





(86) Date de dépôt PCT/PCT Filing Date: 2014/03/19
(87) Date publication PCT/PCT Publication Date: 2014/09/25
(45) Date de délivrance/Issue Date: 2021/02/23
(85) Entrée phase nationale/National Entry: 2015/09/18
(86) N° demande PCT/PCT Application No.: US 2014/031235
(87) N° publication PCT/PCT Publication No.: 2014/153415
(30) Priorité/Priority: 2013/03/19 (US61/803,177)

(51) Cl.Int./Int.Cl. *C07D 405/12* (2006.01),
A61K 31/365 (2006.01), *A61K 31/396* (2006.01),
A61P 35/00 (2006.01), *C07D 307/33* (2006.01)
(72) Inventeurs/Inventors:
KRAVCHENKO, VLADIMIR, US;
ULEVITCH, RICHARD J., US;
JANDA, KIM D., US
(73) Propriétaire/Owner:
THE SCRIPPS RESEARCH INSTITUTE, US
(74) Agent: LAVERY, DE BILLY, LLP

(54) Titre : AMPLIFICATEURS DE TRAIL POUR TUER SELECTIVEMENT DES CELLULES CANCEREUSES
(54) Title: TRAIL ENHANCERS FOR THE SELECTIVE KILLING OF CANCER CELLS



(I);




(II).

(57) **Abrégé/Abstract:**


The invention is directed to methods of inducing apoptosis, arresting cell cycle, or inhibiting cellular proliferation, or any combination thereof, in a tumor cell, by administration of an effective amount of an N-acyl homoserine lactone analog (AHL), optionally in conjunction with a tumor modulating agent such tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) to the patient. Novel bioactive analogs of an N-acyl homoserine lactone are also provided. In embodiments, the N-acyl homoserine lactone analog (AHL) is a compound of formula (I) or (II): (see formula I) (see formula II)

ABSTRACT

The invention is directed to methods of inducing apoptosis, arresting cell cycle, or inhibiting cellular proliferation, or any combination thereof, in a tumor cell, by administration of an effective amount of an N-acyl homoserine lactone analog (AHL), optionally in conjunction with a tumor modulating agent such tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) to the patient. Novel bioactive analogs of an N-acyl homoserine lactone are also provided. In embodiments, the N-acyl homoserine lactone analog (AHL) is a compound of formula (I) or (II):



(I);



(II).

TRAIL ENHANCERS FOR THE SELECTIVE KILLING OF CANCER CELLS

5

BACKGROUND

Apoptosis is a genetically programmed and physiologically important form of cell death. It is a conserved cellular homeostatic mechanism with important roles in normal development through maintaining of cell turn-over in healthy adult tissues. Abnormal apoptotic activity has been linked to the pathogenesis of autoimmune and infectious disorders, including persistent inflammatory diseases (Gyrd-Hansen, et al., *Nat Rev Cancer* 10(8) 561-74). Evading apoptosis has also been identified as a hallmark of cancer (Hanahan D., et al., *Cell* 2000, 100(1), 57-70). Therefore, triggering apoptotic processes may be important for killing cancer cells and sensitizing them to different therapeutic regimens (Ashkenazi, A., *Nat Rev Drug Discov* 2008, 7(12), 1001-12; Ashkenazi, A, et al., *J Clin Invest* 1999, 104(2), 155-62).

Among promising candidates for cancer therapeutics is tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) initiated apoptosis through the receptor-mediated mechanism, also referred to as the extrinsic apoptotic pathway. In contrast to the naturally occurring pro-apoptotic ligands such as TNF and Fas ligand (FasL), TRAIL infusion into mice does not cause a lethal response or detectable toxicity to tissues and organs (Ashkenazi, A., *Nat Rev Drug Discov* 2008, 7(12), 1001-12; Ashkenazi, A, et al., *J Clin Invest* 1999, 104(2), 155-62; Walczak, H. et al., *Nat Med* 1999, 5(2), 157-63). Furthermore, the potential significance of TRAIL for killing cancer cells has been supported by studies in animal models demonstrating that this cytokine possesses selective toxicity to human tumor xenografts but not normal tissues. However, sensitivity

to TRAIL-induced apoptosis is a key factor limiting the efficacy of TRAIL treatment, because a spectrum of sensitivity is observed in different malignant cells (Lippa, M.S. et al., *Apoptosis* 2007, 12(8), 1465). Furthermore, similar to normal cells, some cancer cells are also resistant to TRAIL-induced apoptosis.

5 The increasing understanding of the molecular details of apoptosis indicates that tumor cells can acquire resistance to apoptosis through interference with either extrinsic or intrinsic apoptotic signaling pathways. However, most cancer cells retain the capacity to undergo apoptosis if triggered through mechanisms that can overcome anti-apoptotic influences. For example, inhibition of NF- κ B activity significantly increases apoptosis induced by apoptotic stimuli (Beg, A.A., et al, *Science* 1996, 274 (5288), 782-4; Wang, C.Y., et al., *Science* 1996, 274 (5288), 784-7; Van Antwerp, D.J., et al., *Science* 1996, 274 (5288), 787-9; Liu, Z.G., et al., *Cell* 1996, 87(3), 565-76). In addition, enhancing apoptosis also occurs upon activation of several intracellular non-apoptotic signaling processes, including the JNK pathway or endoplasmic reticular (ER) stress, known in eukaryotic cells as the unfolded protein response (UPR) (Ron, D. et al., *Nat Rev Mol Cell Biol* 2007, 8(7), 519-29). It has been observed that UPR activators such as tunicamycin, thapsigargin and RRR- α -tocopherol ether-link acetic acid analog (α -TEA), sensitize cancer cells to TRAIL-inducing apoptosis (Jiang, C.C., et al., *Cancer Res* 2007, 67(12), 5880; Chen, L.H. et al., *Carcinogenesis* 2007, 28(11), 2328-36; Tiwary, R., et al., *PLoS One* 5(7), e11865). However, these reagents induce constitutive and sustained activation of the UPR.

25 Bacterial metabolites play important roles in inflammation-mediated processes essential for normal development and the pathogenesis of numerous chronic diseases, including cancer. Inflammation is typically initiated as an innate immune response to specific bacterial products through receptor-dependent mechanisms, in which induction of the transcription factor NF- κ B is required for both activation of the immune system and the control of apoptosis in activated cells. For example, in the presence of Gram-negative bacteria, NF- κ B activation is initially induced in response to bacterial lipopolysaccharide (LPS), an agonist of the Toll-like receptor 4 (TLR4), leading to the expression of NF- κ B-regulated genes encoding pro-inflammatory cytokines, such as tumor necrosis factor- α (TNF) and interleukin-1 (IL-1). After the engagement of TNF or

IL-1 receptors, additional rounds of NF- κ B activation amplify this LPS-induced inflammatory response. NF- κ B-dependent processes, in concert with other signaling pathways, up-regulate the expression of pro-apoptotic cancer immunosurveillance effectors, including the TNF-related apoptosis-inducing ligand (TRAIL), an essential mediator of apoptotic cell death particularly in cancer cells. Although the LPS-induced inflammatory response results in the release of pro-apoptotic cytokines such as TNF and TRAIL, cancer cells receiving these death signals can still survive due to the suppressive effects of NF- κ B signaling on apoptosis.


10

SUMMARY

The invention is directed in various embodiments to method of inducing apoptosis, arrest of cell division, or inhibition of cell proliferation, or any combination thereof, in a tumor cell. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) preferentially induces apoptosis in cancer cells over normal cells; however, tumor cells may develop TRAIL resistance. Here we demonstrate that this resistance can be overcome in the presence of bacterial acylhomoserine lactone (AHL) analogs or AHL-producing bacteria through the combined effect of TRAIL-induced apoptosis and AHL-mediated inhibition of inflammation regulated by NF- κ B signaling. This discovery unveils a previously unrecognized symbiotic link between bacteria and host immunosurveillance.

20


The invention provides, in various embodiments, a pharmaceutical composition comprising an effective amount of an N-acylhomoserine lactone (AHL) analog compound of formula (I):



25

wherein R is a linear alkyl, alkenyl or alkynyl of about 9 to about 15 carbon atoms having one or more diazirenyl groups, optionally having one or more carbonyl groups at positions 4 or greater on the alkyl, alkenyl or alkynyl groups, and further optionally substituted with azido, hydroxyl, or halo; or a pharmaceutically acceptable salt thereof; and, optionally, a pharmaceutically acceptable excipient. For example, the AHL compound can be a compound is of formula (II)

30



wherein R¹ is a linear alkyl, alkenyl or alkynyl of about 7 to 13 carbon atoms, optionally having one or more of:

- (a) a diazirenyl group;
- 5 (b) one or more carbonyl groups;
- (c) or, one or more independently selected azido, hydroxyl, or halo groups.

For example, the compound of formula (I) can be the (S)-enantiomer of the compound with respect to the chiral center at the position of bonding of the nitrogen atom to the lactone ring.

In various embodiments, the invention provides a method of treating a tumor in a patient, comprising administering to the patient an effective amount of an N-acylhomoserine lactone (AHL) analog compound of formula (I) as described above. Optionally, an effective amount of a tumor modulating agent such as a TRAIL polypeptide can also be administered.

- 10 In various embodiments, the invention provides a compound or a pharmaceutically acceptable salt thereof described herein for use in treating a tumor in a patient.

- In various embodiments, the invention provides a use of a compound or a pharmaceutically acceptable salt thereof described herein for treating a tumor in a patient.
- 15

In various embodiments, the invention provides a use of a compound or a pharmaceutically acceptable salt thereof described herein for the preparation of a medicament for treating a tumor in a patient.

- In various embodiments, the invention provides a method for inducing
- 20 apoptosis, arrest of cell division, or inhibition of cell proliferation, in a tumor cell, comprising contacting the cell with an effective amount of an N-acylhomoserine lactone (AHL) compound, and, optionally, an effective amount of a tumor modulating agent, such as a TRAIL polypeptide, wherein the AHL compound is of formula (I), as described above.

In various embodiments, the invention provides a compound or a pharmaceutically acceptable salt thereof described herein and a TRAIL ligand, for use in inducing apoptosis, arrest of cell division, or inhibition of cell proliferation, in a tumor cell.

5 In various embodiments, the invention provides a use of a compound or a pharmaceutically acceptable salt thereof described herein and a TRAIL ligand for inducing apoptosis, arrest of cell division, or inhibition of cell proliferation, in a tumor cell.

10 In various embodiments, the invention provides a use of a compound or a pharmaceutically acceptable salt thereof described herein for the preparation of a medicament for the preparation of a medicament for inducing apoptosis, arrest of cell division, or inhibition of cell proliferation, in a tumor cell, wherein the medicament is for use with a TRAIL ligand.


15 In various embodiments, the invention provides methods of synthesis of AHL analogs of the invention, useful for practicing methods of the invention.

20 In various embodiments, the invention provides a kit comprising a compound of the invention, such as compound (S)-(3-N₂), optionally dissolved in a pharmaceutically acceptable liquid medium, in a container; the kit optionally further comprising a tumor modulating agent, such as TRAIL, optionally dissolved in a pharmaceutically acceptable liquid medium, in a second container; further optionally comprising dosing or storage information, or both.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1: C12 induces the UPR in mammalian cells. (A and B).

Comparison of the macrophage responsiveness to *P. aeruginosa* (P.a.), *S. typhimurium* (S.t.), and *S. aureus* (S.a.). RT-PCR assay of *XBPI* (A) and Western blot analysis (B) of p38, its phosphorylated form (p-p38) as well as phosphorylated forms of PERK (p-PERK) and eIF2 α (p-eIF2 α) in cell extracts after treatment with bacteria are shown. (C) Macrophages were stimulated with *P. aeruginosa* wild type (wt) or *lasI* mutant ($\Delta lasI$), and cell extracts (total RNA or total protein) were prepared and analyzed as in (A and B). (D and E) RT-PCR assay of *XBPI* or *actin* in total RNA prepared from macrophages after treatment with compound (C12), i.e., the (S)-enantiomer, or with the (R)-enantiomer (C12R), or the hydrolysis product (C12h) are shown. (F) Total RNA was prepared from lung of mice after inoculation of vehicle (-) or (C12) and analyzed as in (D). (G) Chemical structures of compounds (C12), (C12R) and (C12h). Compound (C12) is the (S)-enantiomer of the compound of formula:

**Figure 2: C12 induces the UPR through modulation of the**

sphingolipid metabolism. (A and B) RT-PCR assays of *XBPI* in total RNA prepared from the macrophages treated with C12, Tm or Tg in the presence or absence of CHX (A) or D-MAPP (B) as indicated. (C) Western blot analysis shows the effect of D-MAPP on (C12)-induced phosphorylation of eIF2 α (p-eIF2 α) and p38 (p-p38); Western blot for actin is a loading control. (D) Macrophages were stimulated with LPS in the presence or absence of D-MAPP, and total protein extracts were prepared and analyzed by Western blot for p-p38 and expression of I κ B α . (E) RT-PCR assay (top panel) or Western blot (bottom panel) monitors the levels of *XBPI* or eIF2 α or p-p38 in samples prepared from macrophages after treatment with (C12), sphingosine (Sph) or dimethylsphingosine (DMS). (F) TLC assay monitors ³H-Sph metabolism in macrophages treated with DMSO (Vehicle) or C12 as indicated. Location of standard sphingolipids is indicated on the left. Cer, ceramide; Sph, sphingosine; SIP, sphingosine 1-phosphate; SM, sphingomyelin.

Figure 3: Sensitivity of cancerous and non-cancerous cells to apoptosis induced by TNF, C12 or a combination of C12 and TNF. Cells were incubated with TNF, (C12) or a combination of TNF and (C12) as indicated, and the cleavage of PARP (an apoptotic marker) was determined by Western blot. **(A and B)** Breast cancer MCF-7 cells transfected with control vector (Vector) and vector expressing Bcl-2 or CLARP. **(C)** HeLa cell line. **(D)** Normal human bronchial epithelial cells (NHBE).

Figure 4: C12 sensitizes lung cancer cell line A549 to TRAIL. **(A)** Viability of cells was examined after 24-hour incubation in media containing TRAIL (50 ng/ml), compound (C12) (1 μ M), compound (C12R) (25 μ M) or the indicated combination of TRAIL (T) with (C12) or (C12R). The chemical structures of (C12) and its stereoisomer (C12R) are shown on the right. **(B)** Viability of cells was examined after 24-hour incubation in media containing TRAIL (50 ng/ml) and the indicated doses of C12. Viable cells remaining after the treatment were determined as a function of mitochondrial activity of living cells according to XTT-based toxicology assay kit (Sigma) and are shown as a percentage of viable untreated cells.

Figure 5: C12 sensitizes lung cancer cell line A549 to TRAIL-induced apoptosis. Cells were treated with TRAIL, (C12) or a combination of TRAIL and (C12) for indicated period of time, and cellular extracts were examined by Western blot analysis for the apoptotic markers (the cleaved form of caspase-9, caspase-3 or PARP), the stress responses (the phosphorylated forms of eIF2 α , p38 or JNK), and actin (a loading control).

Figure 6: Primary human B cells are resistant to TRAIL in the presence of C12. **(A)** Cells were treated by TRAIL (T), (C12), thapsigargin (Tg) or a combination as indicated. Viable cells remaining after a 24-hours treatment were determined as a function of mitochondrial activity of living cells according to XTT-based toxicology assay kit (Sigma) and are shown as a percentage of viable untreated cells. **(B)** Cells were treated 6 hr by TRAIL, (C12), thapsigargin (Tg) or a combination as indicated. The cellular extracts were examined by Western blot for the cleavage of PARP as an apoptotic marker or for actin as a loading control.

Figure 7: Sensitivity of cancerous and non-cancerous cells to a combination of TRAIL and (C12). Normal human bronchial epithelial (NHBE)

and cancerous human HeLa cells were incubated with TRAIL and indicated doses of (C12), and cell viability relative to untreated control was determined by XTT assay.

Figure 8: Safety and pro-apoptotic activity of (C12). Cells were
 5 incubated with TRAIL, (C12), bortezomib (Bor) or a combination of TRAIL and (C12) or Bor as indicated, and cell viability (top panels) or the cleavage of PARP (bottom panels) was determined. **(A)** Lung cancer cell line A549. **(B)** Primary human hepatocytes from normal donor.

Figure 9: Comparison of (C12)-mediated and compound #15-mediated effects on sensitivity of cancerous cells to TRAIL. **(A)** Viability of
 10 A549 cells was examined after 24-hour incubation in media containing TRAIL (25 ng/ml) and the indicated doses of (C12) or its analog (#15) (see Table 1). **(B)** A549 cells were treated by TRAIL, tunicamycin (Tu), thapsigargin (Tg), compound #15, (C12) or a combination as indicated. The cellular extracts were
 15 examined by Western blot for the cleavage of PARP as an apoptotic marker or for actin as a loading control.

Figure 10: Biological activity of the analogs. **(A)** Lung cancer A549 cells were treated by (C12) or its analogs (compound 13, 16 and 17, see Table 1) as indicated, and the cellular extracts were examined by Western blot for the
 20 phosphorylated forms of eIF2 α or p38 and actin as a loading control. **(B)** A549 cells were treated by TRAIL, compound, (C12) or a combination as indicated, and the cellular extracts were prepared (6-hour treatment) and examined by Western blot for the cleavage of PARP as an apoptotic marker as well as indicated in (A).

Figure 11. (C12) -producing bacteria or (C12) promote cytokine-mediated apoptosis in cancer cells. a) Chemical structures of AHLs examined in
 25 this study. b) Lung cancer cells were incubated with or without *P. aeruginosa* (Bac) wild type (wt) or a *lasI* mutant strain ($\Delta lasI$) in the presence or absence of TNF or TRAIL as indicated. After 2 h, cell lysates were prepared and analyzed
 30 by immunoblotting with antibodies specific for PARP or actin as a loading control. c) Lung cells were untreated (Mock) or treated with TNF or TRAIL in the presence of the indicated doses of (C12) for 6 h; cell samples were analyzed as in b). d) Comparison of lung cell responsiveness to TRAIL, (C12) or their combination. Western blot analysis of PARP, I κ B α , the phosphorylated form of

p38 (p-p38) and actin in cellular extracts prepared after treatment with stimuli as indicated.

Figure 12. (C12) promotes the TRAIL-mediated killing of cancer cells.

a), c) Western blot analysis of PARP cleavage in cancer or normal cells treated for 3 h with TRAIL, (C12) or a combination of both, as indicated. b), d) XTT-based assay monitoring the viability of cancer and normal cells grown for 18 h in media containing TRAIL and the indicated doses of (C12). Cell survival was ~100% in control samples (untreated cells) as well as in samples incubated with TRAIL alone or the same doses of (C12) without TRAIL.

Figure 13. AHL-mediated inhibition of inflammation-induced NF- κ B signaling is sufficient for rendering tumors susceptible to TRAIL-induced apoptosis. a) Western blot analysis of PARP cleavage in cancer cells stimulated for 3 h with TRAIL or its combination with different AHLs as indicated. b) Western blot analysis of PARP cleavage as well as phosphorylated forms of eIF2 α and p38 in extracts from bone marrow-derived macrophages (BMDM) stimulated with (C12) or (3-N₂), i.e., (S)-(3-N₂), as indicated. c) Western blot analysis of PARP cleavage and temporal profiles of I κ B α expression in BMDM extracts prepared after treatment with LPS or its combination with (C12) or (3-N₂). d) Inhibitory effect of (C12) and its derivatives on LPS-induced TNF production in BMDM. e) Lung cancer cells were exposed to (3-N₂) (10 μ M), TRAIL (0.5 ng/ml), TNF (20 ng/ml) or their combinations as indicated. After 2 h, cell lysates were prepared and analyzed by Western blot for PARP cleavage, I κ B α and actin.

DETAILED DESCRIPTION

Alkyl groups include straight chain and branched alkyl groups and cycloalkyl groups having from 1 to about 20 carbon atoms, and typically from 1 to 12 carbons or, in some embodiments, from 1 to 8 carbon atoms. Examples of straight chain alkyl groups include those with from 1 to 8 carbon atoms such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups. Examples of branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, t-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups. As used herein, the term “alkyl” encompasses n-alkyl, isoalkyl, and anteisoalkyl groups as well as other branched chain forms of alkyl.

Alkenyl groups include straight and branched chain and cyclic alkyl groups as defined above, except that at least one double bond exists between two carbon atoms. Thus, alkenyl groups have from 2 to about 20 carbon atoms, and typically from 2 to 12 carbons or, in some embodiments, from 2 to 8 carbon atoms. Examples include, but are not limited to vinyl, $-\text{CH}=\text{CH}(\text{CH}_3)$, $-\text{CH}=\text{C}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{C}(\text{CH}_3)=\text{CH}(\text{CH}_3)$, $-\text{C}(\text{CH}_2\text{CH}_3)=\text{CH}_2$, cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, and hexadienyl among others.

Alkynyl groups include straight and branched chain alkyl groups, except that at least one triple bond exists between two carbon atoms. Thus, alkynyl groups have from 2 to about 20 carbon atoms, and typically from 2 to 12 carbons or, in some embodiments, from 2 to 8 carbon atoms. Examples include, but are not limited to $-\text{C}\equiv\text{CH}$, $-\text{C}\equiv\text{C}-\text{CH}_3$, $-\text{C}\equiv\text{C}-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{C}\equiv\text{CH}$, $-\text{CH}_2\text{C}\equiv\text{C}-\text{CH}_3$, and $-\text{CH}_2\text{C}\equiv\text{C}-\text{CH}_2\text{CH}_3$ among others.

When a substituent is more than monovalent, such as O, which is divalent, it can be bonded to the atom it is substituting by more than one bond, i.e., a divalent substituent is bonded by a double bond; for example, a C substituted with O forms a carbonyl group, $\text{C}=\text{O}$, which can also be written as "CO", "C(O)", or "C(=O)", wherein the C and the O are double bonded. When a carbon atom is substituted with a double-bonded oxygen ($=\text{O}$) group, the oxygen substituent is termed an "oxo" group. When it is stated herein that an alkyl, alkenyl, or alkynyl group comprises an carbonyl group, what is referred to is an alkyl, alkenyl, or alkynyl chain respectively wherein a carbon atom of the chain is double bonded to an oxygen atom, e.g., of formula

 wherein a wavy line indicates a point of attachment. The carbonyl group can also be bonded any other carbon atom of the alkyl, alkenyl, or alkynyl.


The terms "halo" or "halogen" or "halide" by themselves or as part of another substituent mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom, preferably, fluorine, chlorine, or bromine.

A "haloalkyl" group includes mono-halo alkyl groups, poly-halo alkyl groups wherein all halo atoms can be the same or different, and per-halo alkyl groups, wherein all hydrogen atoms are replaced by halogen atoms, such as


fluoro. Examples of haloalkyl include trifluoromethyl, 1,1-dichloroethyl, 1,2-dichloroethyl, 1,3-dibromo-3,3-difluoropropyl, perfluorobutyl, and the like.

A "hydroxyl" group is a carbon-bonded OH group.

The term "azido" refers to an N₃ group, of formula




An "diazirenyl" group as the term is used herein refers to a three-membered ring including one carbon atom and two nitrogen atoms, wherein the two nitrogen atoms are double bonded to each other and each nitrogen atom is single bonded to the carbon atom, e.g., of structure:




wherein the tetrahedral carbon atom can be bonded to two further substituents.

When it is stated herein that an alkyl, alkenyl, or alkynyl group comprises a diazirenyl group, what is referred to is an alkyl, alkenyl, or alkynyl chain respectively wherein a saturated carbon atom of the chain is the carbon atom
15 bonded to each of the two nitrogen atoms. For example, a C10 alkyl group comprising a diazirenyl group can be of formula




20 An "N-acylhomoserine lactone (AHL) analog" as the term is used herein can refer to a compound of formula (I)




of the (S) absolute configuration as designated under the Cahn-Ingold-Prelog system, wherein group R is a linear alkyl, alkenyl or alkynyl chain of about 9 to
25 about 15 carbon atoms, which can incorporate diazirenyl groups, carbonyl groups, or both, and can be further substituted with groups as defined above.

An example of a compound of formula (I) is compound (3-N₂)




The diazirene is bonded to the 3-carbon of the acyl chain, and this nomenclature is used throughout.

- 5 As is apparent, a chiral center is present at the position of butyrolactone ring substitution. Accordingly, the compound can be of either configuration, but the (S)-(3-N₂) compound is preferred, which can variously be displayed as



- 10 without any change in the meaning of the structure; both represent the (S)-enantiomer.

There are naturally occurring AHL compounds



- 15 compound (C14),

which can be used in various embodiments of methods of the invention for inducing apoptosis in a tumor cell, or in treating a patient with cancer.

A "salt" as is well known in the art includes an organic compound such as a carboxylic acid, a sulfonic acid, or an amine, in ionic form, in combination

with a counterion. For example, acids in their anionic form can form salts with cations such as metal cations, for example sodium, potassium, and the like; with ammonium salts such as NH_4^+ or the cations of various amines, including tetraalkyl ammonium salts such as tetramethylammonium, or other cations such as trimethylsulfonium, and the like. A "pharmaceutically acceptable" or "pharmacologically acceptable" salt is a salt formed from an ion that has been approved for human consumption and is generally non-toxic, such as a chloride salt or a sodium salt. A "zwitterion" is an internal salt such as can be formed in a molecule that has at least two ionizable groups, one forming an anion and the other a cation, which serve to balance each other. For example, amino acids such as glycine can exist in a zwitterionic form. A "zwitterion" is a salt within the meaning herein. The compounds of the present invention may take the form of salts. The term "salts" embraces addition salts of free acids or free bases which are compounds of the invention. Salts can be "pharmaceutically-acceptable salts." The term "pharmaceutically-acceptable salt" refers to salts which possess toxicity profiles within a range that affords utility in pharmaceutical applications. Pharmaceutically unacceptable salts may nonetheless possess properties such as high crystallinity, which have utility in the practice of the present invention, such as for example utility in process of synthesis, purification or formulation of compounds of the invention.

Suitable pharmaceutically-acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid. Examples of inorganic acids include hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric, and phosphoric acids. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which include formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, trifluoromethanesulfonic, 2-hydroxyethanesulfonic, p-toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, alginic, β -hydroxybutyric, salicylic, galactaric and galacturonic acid. Examples of pharmaceutically unacceptable acid addition salts include, for example, perchlorates and tetrafluoroborates.

Typical compositions include a compound of the invention and a pharmaceutically acceptable excipient which can be a carrier or a diluent. For example, the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which can be in the form of an ampoule, capsule, sachet, paper, or other container. When the active compound is mixed with a carrier, or when the carrier serves as a diluent, it can be solid, semi-solid, or liquid material that acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid carrier, for example contained in a sachet. Some examples of suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatin, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, cyclodextrin, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone. Similarly, the carrier or diluent can include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.

The formulations can be mixed with auxiliary agents that do not deleteriously react with the active compounds. Such additives can include wetting agents, emulsifying and suspending agents, salt for influencing osmotic pressure, buffers and/or coloring substances preserving agents, sweetening agents or flavoring agents. The compositions can also be sterilized if desired.

The route of administration can be any route which effectively transports the active compound of the invention to the appropriate or desired site of action, such as oral, nasal, pulmonary, buccal, subdermal, intradermal, transdermal or parenteral, e.g., rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment, the oral route being preferred.

If a solid carrier is used for oral administration, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge. If a liquid carrier is used, the preparation can be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.

Injectable dosage forms generally include aqueous suspensions or oil suspensions which can be prepared using a suitable dispersant or wetting agent and a suspending agent. Injectable forms can be in solution phase or in the form of a suspension, which is prepared with a solvent or diluent. Acceptable
5 solvents or vehicles include sterilized water, Ringer's solution, or an isotonic aqueous saline solution. Alternatively, sterile oils can be employed as solvents or suspending agents. Preferably, the oil or fatty acid is non-volatile, including natural or synthetic oils, fatty acids, mono-, di- or tri-glycerides.

For injection, the formulation can also be a powder suitable for
10 reconstitution with an appropriate solution as described above. Examples of these include, but are not limited to, freeze dried, rotary dried or spray dried powders, amorphous powders, granules, precipitates, or particulates. For injection, the formulations can optionally contain stabilizers, pH modifiers, surfactants, bioavailability modifiers and combinations of these. The
15 compounds can be formulated for parenteral administration by injection such as by bolus injection or continuous infusion. A unit dosage form for injection can be in ampoules or in multi-dose containers.

The formulations of the invention can be designed to provide quick, sustained, or delayed release of the active ingredient after administration to the
20 patient by employing procedures well known in the art. Thus, the formulations can also be formulated for controlled release or for slow release.

Compositions contemplated by the present invention can include, for example, micelles or liposomes, or some other encapsulated form, or can be administered in an extended release form to provide a prolonged storage and/or
25 delivery effect. Therefore, the formulations can be compressed into pellets or cylinders and implanted intramuscularly or subcutaneously as depot injections. Such implants can employ known inert materials such as silicones and biodegradable polymers, e.g., polylactide-polyglycolide. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides).

30 For nasal administration, the preparation can contain a compound of the invention, dissolved or suspended in a liquid carrier, preferably an aqueous carrier, for aerosol application. The carrier can contain additives such as solubilizing agents, e.g., propylene glycol, surfactants, absorption enhancers

such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabens.

For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in
5 polyhydroxylated castor oil.

Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle
10 can be employed.

A typical tablet that can be prepared by conventional tableting techniques can contain:

Core:

Active compound (as free compound or salt thereof) 250 mg
15 Colloidal silicon dioxide (Aerosil)® 1.5 mg
Cellulose, microcryst. (Avicel)® 70 mg
Modified cellulose gum (Ac-Di-Sol)® 7.5 mg
Magnesium stearate Ad.

Coating:

20 HPMC approx. 9 mg
*Mywacett 9-40 T approx. 0.9 mg

*Acylated monoglyceride used as plasticizer for film coating.

A typical capsule for oral administration contains compounds of the invention (250 mg), lactose (75 mg) and magnesium stearate (15 mg). The
25 mixture is passed through a 60 mesh sieve and packed into a No. 1 gelatin capsule. A typical injectable preparation is produced by aseptically placing 250 mg of compounds of the invention into a vial, aseptically freeze-drying and sealing. For use, the contents of the vial are mixed with 2 mL of sterile physiological saline, to produce an injectable preparation.

30 The compounds of the invention can be administered to a mammal, especially a human in need of such treatment, prevention, elimination, alleviation or amelioration of a malcondition. Such mammals include also animals, both domestic animals, e.g. household pets, farm animals, and non-domestic animals such as wildlife.

The compounds of the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from about 0.05 to about 5000 mg, preferably from about 1 to about 2000 mg, and more preferably between about 2 and about 2000 mg per day can be used. A typical dosage is about 10 mg to about 1000 mg per day. In choosing a regimen for patients it can frequently be necessary to begin with a higher dosage and when the condition is under control to reduce the dosage. The exact dosage will depend upon the activity of the compound, mode of administration, on the therapy desired, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge.


Generally, the compounds of the invention are dispensed in unit dosage form including from about 0.05 mg to about 1000 mg of active ingredient together with a pharmaceutically acceptable carrier per unit dosage.

Usually, dosage forms suitable for oral, nasal, pulmonal or transdermal administration include from about 125 μ g to about 1250 mg, preferably from about 250 μ g to about 500 mg, and more preferably from about 2.5 mg to about 250 mg, of the compounds admixed with a pharmaceutically acceptable carrier or diluent.

Dosage forms can be administered daily, or more than once a day, such as twice or thrice daily. Alternatively dosage forms can be administered less frequently than daily, such as every other day, or weekly, if found to be advisable by a prescribing physician.

Detailed Description

We examined the Gram-negative bacteria *Pseudomonas aeruginosa*, an opportunistic pathogen that is only able to promote infection in hosts with defective immune system functions (Smith, R. S. and Iglewski, B. H. (2003) *Pseudomonas aeruginosa* quorum sensing as a potential antimicrobial target. *J Clin Invest* 112, 1460-5). As compound (C12)




is a signaling molecule produced in abundance by this bacteria, we examined whether wild type *P. aeruginosa* or a mutant strain lacking *lasI*, the gene responsible for the synthesis of compound (C12), could render lung cancer cells susceptible to TNF- or TRAIL-induced cleavage of poly(ADP-ribose) polymerase (PARP), an indicative characteristic of apoptosis. Excitingly, PARP cleavage was only detected when cells received a combination of TRAIL and wild type bacteria (Figure 11b), suggesting that compound (C12) was required for TRAIL-induced apoptosis in cancer cells. Notably, similar results were observed when other AHL-producing bacteria were added to cytokine-stimulated cells, while bacteria that do not possess AHL synthases had no effect. Furthermore, titration experiments confirmed that the direct addition of C12 or several naturally occurring AHL analogues resulted in a strong pro-apoptotic response to TNF or TRAIL, and in agreement with our bacterial experiments, the cells were more sensitive to TRAIL (Figure 11c).

Since activation of NF- κ B signaling inhibits apoptosis, the observed difference in the pro-apoptotic effects of TNF and TRAIL might be linked to the distinct ability of these cytokines to modulate NF- κ B activity. Consistent with this interpretation, Western blot analysis for the degradation and re-synthesis of I κ B α , an indicative biochemical marker of NF- κ B signaling, revealed a robust activation of NF- κ B signaling in response to TNF but not to TRAIL. Although no modulation of NF- κ B or apoptotic signaling was induced in response to TRAIL or compound (C12), substantial changes in the levels of I κ B α were matched with PARP cleavage in lung cancer cells stimulated with a combination of compound (C12) and TRAIL (Figure 11d). Interestingly, we also observed that the combined action of TRAIL and compound (C12) resulted in a prolonged activation of the mitogen-activated protein kinase (MAPK) p38 as determined by Western blot analysis for the phosphorylated form of p38 (Figure 11d; p-p38). These findings suggest that compound (C12) enhances TRAIL's ability to execute apoptosis in cancer cells through modulation of NF- κ B, p38 or both signaling processes.

Despite the expression of TRAIL receptors, normal cells are resistant to TRAIL-induced apoptosis. Similar to non-transformed cells, many malignant cells are not sensitive or only partially sensitive to the pro-apoptotic action of TRAIL. Therefore, in order to assess the selectivity of compound (C12) as a

modulator of TRAIL-dependent tumor immunosurveillance, we compared the sensitivity of several cancer cell lines and normal cells to TRAIL and compound (C12). Consistent with our previous observations, substantial induction of PARP cleavage was observed in lung, colon and breast cancer cells stimulated with a combination of compound (C12) and TRAIL. In contrast, human hepatocytes from normal donors as well as other primary cells from normal tissues were resistant to the same treatment (Figures 12a and 12c). Importantly, longer treatment of cancer cells with TRAIL plus compound (C12) significantly decreased their viability although no effect on the survival of normal cells was noted (Figures 12b and 12d).

While these data demonstrate a therapeutic potential of compound (C12) as an enhancer of TRAIL-dependent anticancer activity, questions concerning (C12)-mediated pro-apoptotic effects on immune cells, such as primary macrophages, were still required to be addressed. Considering the potential inherent pharmacokinetic liabilities associated with C12, a small series of compound (C12) analogues was tested against bone marrow-derived macrophages and TRAIL-treated lung cancer cells. From these studies, an AHL lacking the 3-oxo moiety was found to be completely inactive in both assays; however, a 3-diazirine-containing derivative of compound (C12) termed compound (3-N₂)



the (S)-enantiomer of which is referred to, wherein a diazirine ring (i.e., containing a double bond between the two nitrogen atoms) replaces the carbonyl group of compound (C12); (see the Examples, below, for structure, synthesis and characterization data) was found to be nontoxic to macrophages, yet exhibited toxicity against TRAIL-treated cancer cells in a manner similar to the parental molecule. Moreover, we also observed a comparable effect of compound (C12) and compound (3-N₂) on TRAIL-induced PARP cleavage in TRAIL resistant cancer cells (Figure 13a).

To better define the structure-activity relationship between AHL-mediated effects on the pro-apoptotic action of TRAIL and the agonistic

potential of (C12) or compound (3-N₂), the responses of macrophages to these compounds were examined by Western blot analysis for PARP cleavage, activation of p38, and the phosphorylation of the eukaryotic translation initiation factor 2 α (eIF2 α), a distinct feature of mammalian cell activation in response to

5 C12 and its 3-oxo-analogues. A comparison of the agonistic activities of compound (C12) and compound (3-N₂) revealed that both compounds induced eIF2 α phosphorylation in a similar fashion; however, compound (3-N₂) did not induce p38 phosphorylation and PARP cleavage (Figure 13b), suggesting that activation of the p38 pathway promotes AHL-induced apoptosis in addition to

10 stimulating phagocytic activity, as previously disclosed.

Besides its agonistic activities, compound (C12) also inhibits inflammatory responses to TNF, LPS and other TLR ligands in a wide variety of cell types. In macrophages, the anti-inflammatory activity of C12 interferes with the inducible expression of NF- κ B target genes, such as I κ B α and TNF. Our

15 results also suggest that AHL-mediated disruption of I κ B α -dependent NF- κ B signaling renders cancer cells susceptible to TNF- and TRAIL-induced apoptosis (see Figure 11d). Therefore, to examine whether compound (3-N₂) affects stimulus-induced NF- κ B signaling, we compared the dynamics of I κ B α expression in macrophages activated by LPS or its combination with compound

20 (C12) or compound (3-N₂). Curiously, although the expected pro-apoptotic cleavage of PARP was observed in the presence of compound (C12) but not compound (3-N₂), both compounds were equally effective in blocking LPS-induced re-synthesis of I κ B α (Figure 13c). Moreover, similarity between the anti-inflammatory activities of compound (C12) and compound (3-N₂) were also

25 evident from comparison of their inhibitory effects on LPS-induced production of TNF (Figure 13d). These experiments indicate that compound (3-N₂) is nontoxic to resting or inflammation-activated macrophages; however, it retains the ability of C12 to modulate LPS-induced NF- κ B signaling.


TNF is a key inflammatory mediator responsible for LPS-induced tumor

30 growth, and the growth-promoting activity of TNF is dependent on NF- κ B activation. Most importantly, experiments using a mouse model of LPS-induced tumor growth suggest that inhibition of TNF-mediated NF- κ B signaling in cancer cells converts inflammation-induced tumor growth to inflammation-induced tumor regression mediated by endogenous TRAIL. To address whether

an AHL is able to enhance the anti-cancer activity of TRAIL in inflammation-activated cancer cells, we examined the effect of a suboptimal concentration of TRAIL on PARP cleavage in cancer cells treated with a combination of TNF and compound (3-N₂). Western blot analysis revealed that TRAIL-dependent
 5 PARP cleavage was manifested in cancer cells stimulated with TNF in the presence of compound (3-N₂), and significantly, the TRAIL-mediated apoptotic response coincided with disruption of TNF-induced NF-κB signaling (Figure 13e).

In sum, the identification of compound (C12) and its analogues such as
 10 compound (3-N₂) as “TRAIL-enhancers” and the ability of these compounds to inhibit pro-inflammatory responses through modulation of NF-κB signaling provide a proof-of-principle application for the selective killing of cancer cells. Notably, the synergistic effects of compound (3-N₂) on TRAIL-induced apoptosis in cancer cells were comparable with those for an anti-cancer agent
 15 bortezomib; however, in contrast to bortezomib, compound (3-N₂) alone or in combination with TRAIL was non-toxic to human hepatocytes derived from tissues of normal donors. A linkage of cancer and inflammation suggests a substantial benefit can be gained from using anti-inflammatory agents, such as inhibitors of NF-κB, in cancer therapy and prevention.

20 Accordingly, in various embodiments, the invention provides a pharmaceutical composition comprising an effective amount of an N-acylhomoserine lactone (AHL) analog compound of formula (I):




wherein R is a linear alkyl, alkenyl or alkynyl of about 9 to about 15 carbon
 25 atoms having one or more diazirenyl groups bonded thereto, optionally having one or more carbonyl groups at positions 4 or greater on the alkyl, alkenyl or alkynyl groups, and further optionally substituted with azido, hydroxyl, or halo; or a pharmaceutically acceptable salt thereof; and, optionally, a pharmaceutically acceptable excipient.

30 In reference to the statement about optionally having one or more carbonyl groups at positions 4 or greater on the alkyl, alkenyl or alkynyl groups,

the position number (e.g., 4) refers to the carbon number of the acyl chain to which the oxygen atom is bonded (e.g., at position 4 of the acyl chain). The acyl chain forms an amide bond with the homoserine lactone amino group to provide the AHL compound.

5 For example, the AHL compound can be of formula (II)







wherein R¹ is a linear alkyl, alkenyl or alkynyl of about 7 to 13 carbon atoms, optionally having one or more of:


- (d) a diazirenyl group;
- 10 (e) one or more carbonyl groups; or
- (f) one or more independently selected azido, hydroxyl, or halo groups.

In various embodiments, a pharmaceutical composition of the invention can further comprising a tumor modulating agent that is a TRAIL polypeptide.


15 More specifically, the N-acylhomoserine lactone (AHL) analog is selected from the group consisting of:



In various embodiments, the invention provides a method of treating a tumor in a patient, comprising administering to the patient an effective amount of an N-acylhomoserine lactone (AHL) analog compound of formula (I)



5 wherein R is a linear alkyl, alkenyl or alkynyl of about 9 to about 15 carbon atoms having one or more diazirenyl groups, optionally having one or more carbonyl groups, and further optionally substituted with azido, hydroxyl, or halo; or a pharmaceutically acceptable salt; and optionally, a pharmaceutically
10 acceptable excipient. For instance, the compound can be a compound of formula (II)





wherein R¹ is a linear alkyl, alkenyl or alkynyl of about 7 to 13 carbon atoms, optionally having one or more of:

- 15 (a) a diazirenyl group;
(b) one or more carbonyl groups; or
(c) one or more independently selected azido, hydroxyl, or halo groups.

The method of the invention can further comprise administering an effective amount of a tumor modulating agent that is a TRAIL polypeptide.


20 More specifically the N-acylhomoserine lactone (AHL) analog can be selected from the group consisting of:






For example, the tumor that can be treated according to a method of the invention can be selected from the group consisting of lung, cervical, breast, and brain tumors.

The invention provides, in various embodiments, a method for inducing apoptosis, arrest of cell division, or inhibition of cell proliferation, in a tumor cell, comprising contacting the cell with an effective amount of an N-acylhomoserine lactone (AHL) compound, and an effective amount of a TRAIL, wherein the AHL compound is of formula (I):



wherein R is a linear alkyl, alkenyl or alkynyl of about 9 to about 15 carbon atoms having one or more diazirenyl groups, optionally having one or more carbonyl groups, and further optionally substituted with azido, hydroxyl, or halo. For example, in various embodiments, the AHL analog in the effective amount is an activator of the unfolded protein response (UPR), of endoplasmic reticulum swelling (ERS), or both, in the tumor cell.





More specifically, for practice of a method of the invention, the AHL compound is a compound of formula (II)



wherein R^1 is a linear alkyl, alkenyl or alkynyl of about 7 to 13 carbon atoms, optionally having one or more of:


- (a) a diazirenyl group;
- (b) one or more carbonyl groups; and
- 5 (c) one or more independently selected azido, hydroxyl, or halo groups.

More specifically, the N-acylhomoserine lactone (AHL) analog can be selected from the group consisting of:




The tumor cell can be from a tumor selected from the group consisting of lung, cervical, breast, and brain tumors.

- 15 The present invention further provides, in various embodiments, a compound of formula (I):



- wherein R is a linear alkyl, alkenyl or alkynyl of about 9 to about 15 carbon atoms having one or more diazirenyl groups, optionally having one or more carbonyl groups at positions 4 or greater on the alkyl, alkenyl or alkynyl groups, and further optionally substituted with azido, hydroxyl, or halo; or, a
- 20

pharmaceutically acceptable salt thereof. For example, the compound can be a compound of formula (II)







wherein R¹ is a linear alkyl, alkenyl or alkynyl of about 7 to 13 carbon atoms,


optionally having one or more of:

- (a) a diazirenyl group;
- (b) one or more carbonyl groups; or
- (c) one or more independently selected azido, hydroxyl, or halo groups.

The compound of formula (I) as described above can be provided in a pharmaceutical combination with a tumor modulating agent that is a TRAIL polypeptide. For example, the N-acylhomoserine lactone (AHL) analog of the invention can be selected from the group consisting of:




In various embodiments, the invention provides a method of inducing apoptosis in a cell comprising contacting the cell with an effective amount of the N-acylhomoserine lactone (AHL) analog as described above, provided the AHL analog is not of formulas




Optionally, the method of inducing apoptosis further comprises administering an effective amount of a tumor modulating agent, such as TRAIL. The method of inducing apoptosis can be selective for a cancer cell with respect to a normal cell.

In various embodiments, the invention provides a method of treating a tumor in a patient, comprising administering to the patient an effective amount of an N-acylhomoserine lactone (AHL) analog, plus an effective amount of a tumor modulating agent, such as TRAIL. In various embodiments, the AHL analog is not of formulas




In various embodiments, the method of treating a tumor can provide
15 selective killing of cells of the tumor in the presence of normal cells of the
patient's body.

The compound of formula (I) can be a compound of formula (3-N₂)




For example, the compound of formula (I) can be the (S)-enantiomer of a
20 compound of formula (3-N₂)




In various embodiments, the invention provides a compound of formula

(I)




- 5 wherein R is a linear alkyl, alkenyl or alkynyl of about 9 to about 15 carbon atoms, comprising one or more diazirenyl group, optionally further comprising one or more a carbonyl group, and further optionally substituted with azido, hydroxyl, or halo, or a pharmaceutically acceptable salt thereof, provided that the compound is not



In various embodiments, the invention provides a compound of formula

(3-N₂)







- 15 wherein the diazirine ring, containing a double bond between the two nitrogen atoms, replaces the carbonyl group of the compound C12 to provide compound (3-N₂).

- In various embodiments, the invention provides a pharmaceutical composition comprising a compound of the invention, and a pharmaceutically acceptable excipient.

In various embodiments, the invention provides a kit comprising a compound of the invention, optionally dissolved in a pharmaceutically acceptable liquid medium, in a container; the kit optionally further comprising a tumor modulating agent, such as TRAIL, optionally dissolved in a pharmaceutically acceptable liquid medium, in a second container; further optionally comprising dosing or storage information, or both.


More specifically, the N-acylhomoserine lactone (AHL) analog of formula (I) as disclosed and claimed herein can be any of:



or any pharmaceutically acceptable salt thereof.

The tumor can be a lung tumor, a cervical tumor, breast cancer, brain cancer, or the like. In various embodiments, the AHL analog of formula (II) can be in an effective amount an activator of the unfolded protein response (UPR), of endoplasmic reticulum swelling (ERS), or both, in the tumor cell.


In various embodiments, the invention provides a method of inducing an unfolded protein response (UPR) in a mammalian cell comprising contacting the cell with an effective amount of an AHL or analog thereof of formula (I)



wherein R is a linear alkyl, alkenyl or alkynyl of about 9 to about 15 carbon atoms, comprising one or more diazirenyl group, optionally further comprising

one or more a carbonyl group, and further optionally substituted with azido, hydroxyl, or halo, or a pharmaceutically acceptable salt thereof.


In various embodiments, the UPR thus induced can produce cell cycle arrest and/or can inhibit cell division or proliferation. Cell cycle arrest and/or inhibition of cell division or proliferation can be an effective therapy in treating neoplasms such as tumors. Accordingly, in various embodiments, the invention provides a method of treating a malcondition in a patient wherein induction of the UPR, arrest of cell division and/or inhibition of cell proliferation is medically indicated, comprising administering to the patient an effective amount of an AHL or analog thereof of formula (I)



wherein R is a linear alkyl, alkenyl or alkynyl of about 9 to about 15 carbon atoms, comprising one or more diazirenyl group, optionally further comprising one or more a carbonyl group, and further optionally substituted with azido, hydroxyl, or halo, or a pharmaceutically acceptable salt thereof.


The method of treatment comprising induction of the UPR can further comprise co-administration of an effective amount or concentration of a TRAIL. For example, the malcondition can comprise cancer or a precancerous condition or tissue hyperplasia.

The invention further provides, in various embodiments, a pharmaceutical composition comprising an effective amount of an N-acylhomoserine lactone (AHL) analog from a compound of formula (I):



wherein R is a linear alkyl, alkenyl or alkynyl of about 9 to about 15 carbon atoms having one or more diazirenyl groups, optionally having one or more carbonyl groups at positions 4 or greater on the alkyl, alkenyl or alkynyl groups, and further optionally substituted with azido, hydroxyl, or halo; and

a pharmaceutically acceptable salt. For example, the compound can be a compound of formula (II)




wherein R¹ is a linear alkyl, alkenyl or alkynyl of about 7 to 13 carbon atoms,

5 optionally having:

- (g) a diazirenyl group;
- (h) one or more carbonyl groups; and
- (i) optionally substituted with azido, hydroxyl, or halo.


In various embodiments, the invention can further provide the
10 pharmaceutical composition as described above, further comprising a tumor modulating agent that is a TRAIL polypeptide.

More specifically, the invention provides the pharmaceutical composition as described above, wherein the N-acylhomoserine lactone (AHL) analog is selected from the group consisting of:




In various embodiments, the invention provides a method of treating a
20 tumor in a patient, comprising administering to the patient an effective amount

of an N-acylhomoserine lactone (AHL) analog comprising a compound of formula (I)




- 5 wherein R is a linear alkyl, alkenyl or alkynyl of about 9 to about 15 carbon atoms having one or more diazirenyl groups, optionally having one or more carbonyl groups, and further optionally substituted with azido, hydroxyl, or halo; and
a pharmaceutically acceptable salt. For example, to practice a method of the
10 invention, the compound can be a compound of formula (II)




wherein R¹ is a linear alkyl, alkenyl or alkynyl of about 7 to 13 carbon atoms, optionally having:

- (d) a diazirenyl group;
15 (e) one or more carbonyl groups; and
(f) optionally substituted with azido, hydroxyl, or halo.


For example, the method of treating a tumor in a patient as described above can further comprise administering a tumor modulating agent that is a TRAIL polypeptide. for instance, for practicing the method of treating a tumor
20 in a patient as described above, the N-acylhomoserine lactone (AHL) analog can be selected from the group consisting of:






For example the tumor can be selected from the group consisting of lung,
 5 cervical, breast, and a brain tumors.

The invention further provides, in various embodiments, a compound of
 formula (I):







wherein R is a linear alkyl, alkenyl or alkynyl of about 9 to about 15 carbon
 10 atoms having one or more diazirenyl groups, optionally having one or more
 carbonyl groups at positions 4 or greater on the alkyl, alkenyl or alkynyl groups,
 and further optionally substituted with azido, hydroxyl, or halo; and
 a pharmaceutically acceptable salt. For example, the compound can be a
 compound of formula (II)




wherein R¹ is a linear alkyl, alkenyl or alkynyl of about 7 to 13 carbon atoms,
 optionally having:

- (d) a diazirenyl group;
- (e) one or more carbonyl groups; and
- 20 (f) optionally substituted with azido, hydroxyl, or halo.

The compound can be combined with a tumor modulating agent that is a TRAIL polypeptide. The compound of the invention can be selected from the group consisting of:




The invention further provides, in various embodiments, a method for inducing apoptosis, arrest of cell division, or inhibition of cell proliferation, in a tumor cell, comprising contacting the cell with an effective amount of an N-acylhomoserine lactone (AHL) compound, and an effective amount of a TRAIL, wherein the compound is from formula (I):



wherein R is a linear alkyl, alkenyl or alkynyl of about 9 to about 15 carbon atoms having one or more diazirenyl groups, optionally having one or more carbonyl groups, and further optionally substituted with azido, hydroxyl, or halo. More specifically, the for practice of the method for inducing apoptosis, arrest of cell division, or inhibition of cell proliferation, in a tumor cell, the AHL analog in the effective amount can be an activator of the unfolded protein response (UPR), of endoplasmic reticulum swelling (ERS), or both, in the tumor cell.

For instance, for practice of a method of the invention as described above, the compound can be a compound of formula (II)







wherein R¹ is a linear alkyl, alkenyl or alkynyl of about 7 to 13 carbon atoms, optionally having:

(d) a diazirenyl group;

(e) one or more carbonyl groups; and

optionally substituted with azido, hydroxyl, or halo.

More specifically, for practice of the method for inducing apoptosis, arrest of cell division, or inhibition of cell proliferation, in a tumor cell, the N-acylhomoserine lactone (AHL) analog can be selected from the group consisting of:



In various embodiments, the invention provides a kit comprising a AHL analog, or an compound of the invention, optionally dissolved in a pharmaceutically acceptable liquid medium, in a container; the kit optionally further comprising a tumor modulating agent, optionally dissolved in a

pharmaceutically acceptable liquid medium, in a second container; further optionally comprising dosing or storage information, or both.

Biological Studies

Previous work by the inventors here have shown that bacterial N-(3-oxo-acyl) homoserine lactones (AHLs) transiently induce distention of the ER and appearance of a biochemical marker of the UPR, such as phosphorylation of eukaryotic translation initiation factor 2 α (eIF2 α), suggesting roles of AHLs in the UPR (V. Kravchenko, et al., *J Biol Chem* 2006, 281(39), 28822-30). Since the inositol-requiring protein 1 (IRE1)-mediated splicing of the mRNA encoding the transcription factor XBP1 (X-box binding protein) is an evolutionary conserved signature of the UPR (Schroder, M., et al, *Ann Rev Biochem* 2005, 74, 739-89), we addressed the role of AHLs in activation of the UPR by investigating if the spliced form of XBP1 mRNA (sXBP1) is generated in response to the presence of N-(3-oxo-acyl-dodecanoyl) homoserine lactone ("C12"). An RT-PCR assay revealed that compound C12 as well as other AHLs induced the generation of sXBP1 in mouse embryonic fibroblasts (MEFs) and the response to C12 was comparable with the effects of tunicamycin (Tg) and thapsagargin (Tg). This response to C12 was not limited to MEFs, but was also observed in a wide variety of cell types, including human transformed cells.

The bacterial super community, also referred to as the microbiota, coexists with multi-cellular organisms and is the ancient environment factor with important roles in numerous stress-sensing physiological processes, particularly those involved in metabolic and immune responses of the host cells. For example, the gut microbiota beneficially contributes to both the metabolic system by promoting the harvest of dietary nutrients^{1,2} and the immune system by maintaining the normal low-grade level of inflammation²⁻⁴. Traditionally, inflammatory process is required for tissue repair and involves integration of many complex signaling mechanisms including modulation of the Toll-like receptor (TLR) pathways in response to bacterial products such as lipopolysaccharide (LPS) and peptidoglycan^{4,5}. On the other hand, the microbiota-mediated inflammation is also associated with metabolic disorders such as obesity and cancer development^{2,6-8}. Although the molecular mechanisms underlining these disorders are inextricable interconnected with

activation of the endoplasmic reticulum (ER) stress pathway^{5,9,10}, the bacterial component(s) triggering ER stress has yet to be identified.

Among key biochemical signatures of the multicomponent ER stress pathway, known as the unfolded protein response (UPR), are the phosphorylation of the α -subunit of eukaryotic translation initiation factor-2 (eIF2 α) and activation of the transcription factor XBP1/Hac1 (X-box binding protein-1 in metazoans and homologous to ATF/CREB in yeast, respectively)¹¹. The ability of certain Gram-negative bacterium-derived molecules, such as *N*-(3-oxo-acyl) homoserine lactones (3-oxo-AHLs), to induce eIF2 α phosphorylation¹² as well as the presence of 3-oxo-AHLs in samples of the microbiota¹³⁻¹⁵ prompted us to investigate their role in activation of the UPR. The Gram-negative *Pseudomonas aeruginosa* and Gram-positive *Staphylococcus aureus* bacteria were chosen as two evolutionary distant microbes that can form part of human microbiota, and activate mammalian cells mainly through TLR4 and TLR2, respectively^{4,16}; unlike to *S. aureus*, *P. aeruginosa* also represents a class of bacteria synthesizing a prototypic member of the 3-oxo-AHL family, *N*-(3-oxo-dodecanoyl) homoserine lactone compound (C12). Additionally, the Gram-negative bacterium *Salmonella typhimurium* was used as a control microbe that contains TLR4 ligands similar to those in *P. aeruginosa*, but does not synthesize compound (C12)¹⁷. To initiate our studies, we exposed bone marrow-derived macrophages (BMDM) to these bacteria, and macrophage responsiveness was analyzed for biochemical markers of the UPR and the phosphorylation of the mitogen-activated protein kinase p38, as a common marker of TLR pathways. Rapid and robust generation of the spliced form of *XBPI* mRNA (*sXBPI*) was observed in response to *P. aeruginosa*, whereas two other bacteria induced very faint, if any, level of *sXBPI* (Fig. 1A). Moreover, although all three bacteria induced similar levels of p38 phosphorylation (p-p38), additional signs of the UPR, such as the phosphorylated forms of eIF2 α and PERK [the double-stranded RNA-dependent protein kinase (PRK)-like ER kinase], were only observed in response to *P. aeruginosa* (Fig. 1B). Notably, we found that *P. aeruginosa* deficient in *lasI*, the gene responsible for compound (C12) synthesis, lost the ability to activate *sXBPI* and eIF2 α phosphorylation (Fig. 1C), providing evidence that the observed induction of the UPR markers was linked to the presence of C12 in wild type *P. aeruginosa*. Indeed, direct

addition of C12 resulted in time- and dose-dependent induction of *sXBP1* (Fig. 1D and 1E). Such activation of the UPR was selective to the natural (S)-form of compound (C12), whereas an unnatural (R)-stereoisomer (C12R) or a hydrolyzed form of compound (C12), (C12h), was ineffective (Figure 1D and 1G).

Importantly, the similar requirements in the structural integrity of the lactone ring motif were also evident in response to other natural stereoisomer of the AHL family (Table 1). These effects of AHLs on the UPR activation were not limited to macrophages, but were also observed in other cell types including mouse embryonic fibroblasts (MEF), normal human bronchial epithelial cells and human TPH1 cell line (Table 2). More importantly, administration of C12 into mouse lung resulted in the generation of *sXBP1* (Fig. 1F), consistent with our experiments in cultured cells. Thus, AHLs represent the first example of secreted bacterial molecules that possess the ability to induce the UPR in various mammalian cells.

Modulation of the sphingolipid metabolism by C12 results in activation of the UPR.

The unfolded protein response relies on both protein and lipid components of the ER¹¹. To clarify whether C12 targets protein component of the ER, we examined the effect of a general protein synthesis inhibitor CHX on *sXBP1* induction in response to C12, tunicamycin (Tm, an inhibitor of protein glycosylation affecting the folding of newly synthesized protein) or thapsigargin (Tg, an inducer of passive release of calcium from ER stores resulting to activation of the UPR independently from *de novo* protein synthesis). Compared to Tg and especially to Tm, C12-induced generation of *sXBP1* was completely resistant to CHX (Fig. 2A), suggesting that a protein component of the ER stress is dispensable for the C12-induced UPR activation.

It has been suggested that the biosynthesis of lipids and regulation of the UPR are linked, although the specific lipid components involved in modulation of the UPR have not defined yet^{10, 11, 18}. Since *de novo* synthesis of the core sphingolipid, N-acyl-sphingosine or ceramide (Cer), occurs in the ER¹⁰, we sought to test whether pharmacological inhibitors of sphingolipid metabolism alter the UPR activation by C12. The results of these experiments identified D-MAPP, an inhibitor of Cer cleavage, as an agent that substantially impaired C12-

induced phosphorylation of eIF2 α (Fig. 2B). The inhibitory effect was specific to C12-mediated UPR activation, as both Tm- and Tg-mediated induction of *sXBP1* was unchanged in the presence of D-MAPP (Fig. 2C); additionally, LPS-induced activation of p38 phosphorylation and the profiles of I κ B α expression
 5 were also unaltered by D-MAPP (Fig. 2D). Thus, these findings suggest that both IRE1 and PERK arms of the UPR sense and respond to changes in sphingolipid metabolism induced by C12.

The backbone component of all sphingolipids, sphingosine (Sph), is a product of Cer cleavage. Acylation of the Sph amino group with fatty acids
 10 recycles Cer, whereas the phosphorylation of Sph results in production of sphingosine 1-phosphate (S1P), hydrolysis of which represents the final step of the metabolic pathway^{10, 19}. Sph also can be *N*-methylated to *N,N*-dimethylsphingosine (DMS) that acts as a naturally occurred inhibitor of the sphingosine kinase activity; and its addition to the cells results in a decrease in
 15 S1P and accompanies with small increase in Sph levels^{20, 21}. Toward this end, our data showed that modulation of the Sph metabolism was correlated with the UPR activation, because the expected increase in intracellular Sph level due to DMS treatment resulted in the induction of *sXBP1* and eIF2 α phosphorylation, whereas the extracellular addition of Sph had no effect on these biochemical
 20 markers of the UPR (Fig. 2E). Therefore, to address whether C12 modulates metabolic conversion of intracellular Sph, BMDM were radiolabeled with ³H-Sph in the absence or presence of C12, and the distribution of radioactivity within the sphingolipid fractions was estimated by thin layer chromatography (TLC). We found that substantial amount of ³H-radioactivity was rapidly (within
 25 5 min) incorporated into the Cer fraction, and two hours later, it was distributed between the ceramide and sphingomyelin (SM) fractions. Addition of C12 dramatically changed the early, as well as the late steps of sphingolipid metabolism; after 2 hr the expected incorporation into the sphingomyelin was not observed but rather the radioactivity remained in the sphingosine fraction
 30 (Fig. 2F). Moreover, a 5-min treatment with C12 also resulted in the incorporation of ³H-radioactivity into another fraction (presumably S1P) that diminished over time. Although further detailed studies of mechanisms involved in these processes are needed, these finding provide a first piece of evidence that C12 possesses the ability to modulate the metabolism of sphingolipids, perhaps

through the steps involved in Sph turnover and generation, and this effect of C12 correlates with activation of the UPR. Thus, we postulate that C12 induces cell activation through modulation of the metabolism of sphingolipids.

C12 possesses the ability to act as a cancer-stop and cancer preventing agent.

5 Ceramide (Cer), sphingosine (Sph) and Sph-1-phosphate (S1P) represent general signaling lipids with critical roles in defense mechanisms regulating apoptotic removal of damaged cells to prevent autoimmunity and cancer development^{9, 10, 19, 22}.

10 In eukaryotes, sphingolipids are synthesized *de novo* in the endoplasmic reticulum (ER) via biosynthetic pathway, in which *N*-acyl-sphingosine or Cer is a core metabolite that can be further modified to produce sphingomyelins or more complex glycosphingolipids. In contrast to Cer, D-erythro-sphingosine (Sph) is formed only in a result of Cer cleavage, whereas acylation of the Sph amine group with fatty acids recycles the Cer. Moreover, although both phosphorylated products of Cer and Sph, C1P and S1P respectively, may be salvaged by
15 dephosphorylation, S1P can be irreversibly cleaved. Once generated, these molecules become “bioactive” lipids that regulate the diverse cellular functions in a manner distinct from the canonical paradigm of the linear signaling pathway¹⁰. The unique complexity of sphingolipid signaling is not only in their metabolic
20 interconversion, but also is the opposite effect of individual bioactive lipids on given pathway. For example, Sph acts as a negative regulator of cell growth and promotes the stimuli-induced apoptotic pathways²¹⁻²⁴, while its phosphorylated counterpart S1P induces the cell proliferation and protects from apoptosis^{22, 24, 25}. In fact, a number of environmental and endogenous factors/conditions alter
25 the metabolism of sphingolipids¹⁰. Since several of these conditions are also associated with development and progression of metabolic diseases and cancer, it is logical to consider that an enhance of sphingolipid-mediated apoptotic signaling could stop the disease progressing from any stage if a given agent leaves healthy cells intact while inducing cancerous cells to self-destruct.

30 In this regard, the ability of C12 to affect Sph metabolism (see above Fig. 2) suggested that C12 acts as a potential cancer-stop and cancer preventing agent through selective activation of apoptosis in transformed cells or inflammation-damaged cells, such as macrophages that produces tumor necrosis factor (TNF), an inflammatory cytokine. Consistent with this assumption, our previously

published data revealed that C12 treatment of myeloid cells results in rapid induction of apoptosis, although non-myeloid cells show significantly delayed kinetics and reduction of the apoptotic marker expression (see Fig.3 in Kravchenko et al., 2006; ref #12).

5 To further test this hypothesis, we compared sensitivity of breast cancer cell line MCF7 to apoptosis induced by TNF, C12 or their combination. In these experiments we used a control variant of MCF7 (Vector) as well as MCF7 cells stably expressing negative regulators of apoptosis, such as Bcl-2 and CLARP; Bcl-2 is an inhibitor of the intrinsic apoptotic pathway, whereas CLARP inhibits
10 receptor-dependent apoptotic signaling, also called the extrinsic apoptotic pathway. The cells were incubated with TNF, C12 or their combination, and protein extracts were analyzed by Western blot for the cleavage of PARP, a biochemical marker indicative of apoptosis²⁶. As expected, prolong incubation of control and MCF7/Bcl-2 cells with TNF induced the cleavage of PARP,
15 whereas MCF7/CLARP cells were resistant to TNF-mediated apoptosis (Fig. 3A). In contrast, all three cell lines showed sensitivity to C12; also, the synergy between C12 and TNF was evident in all three cell lines treated by a combination of both stimuli (Fig. 3B).

Similar experiments were conducted by using normal human bronchial
20 epithelial cells and HeLa cell line as an example of transformed cells. We observed that both HeLa and normal cells were resistant to pro-apoptotic effects of TNF (Fig. 3C and 3D). Normal cells also showed resistance to C12 and its combination with TNF (Fig. 3D), although C12 alone induced the cleavage of PARP in HeLa cells. Notably, strong synergism was observed between TNF and
25 C12 in HeLa cells (see Fig. 3C). Thus, these data further support our assumption that C12 induces apoptosis in cancer cells, while normal cells are relatively resistant to C12 or its combination with TNF. In addition, two stimuli – C12 and TNF – work synergistically against cancerous cells, although normal cells stay intact.

30 *A combination of TRAIL and C12 or an analog synergistically kills cancerous cells.*

Among a promising candidate for cancer therapeutics is tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). Similar to other members of the TNF family, TRAIL initiates apoptosis through the receptor-

mediated mechanism, also referred to as the extrinsic apoptotic pathway. In contrast to other naturally occurring pro-apoptotic ligands such as TNF and Fas ligand (FasL), TRAIL infusion into mice does not cause a lethal response or detectable toxicity to tissues and organs²⁷⁻²⁹. Furthermore, the potential
 5 significance of TRAIL for killing cancer cells has been supported by studies in animal models demonstrating that this cytokine possesses selective toxicity to human tumor xenografts but not normal tissues^{28,29}. However, sensitivity to TRAIL-induced apoptosis is a key factor limiting the efficacy of TRAIL
 10 cells^{27, 28, 30}. Furthermore, similar to normal cells, some cancer cells are also resistant to TRAIL-induced apoptosis, although the basis for the sensitivity and resistance of cells to TRAIL-mediated effects is not fully understood.

The increasing understanding of the molecular details of apoptosis indicates that tumor cells can acquire resistance to apoptosis through interference
 15 with either extrinsic or intrinsic apoptotic signaling pathways, which commonly accompanies with defects in cell growth control or/and with an increase in the anti-apoptotic activity of survival pathways such as the NF- κ B and Akt signaling cascades. Indeed, most cancer cells retain the capacity to carry out apoptosis if triggered through mechanisms that can overcome such anti-apoptotic activities.
 20 For example, inhibition of NF- κ B activity significantly increases apoptosis induced by apoptotic stimuli³¹⁻³⁴. In addition, enhancing apoptosis also occurs upon activation of several intracellular non-apoptotic signaling processes, including the JNK pathway or endoplasmic reticular (ER) stress, known in eukaryotic cells as the unfolded protein response (UPR)¹¹. Remarkably, recent
 25 observations revealed that the UPR activators, such as tunicamycin (Tm), thapsigargin (Tg) and RRR- α -tocopherol ether-link acetic acid analog (α -TEA), sensitize cancer cells to TRAIL-induced apoptosis³⁵⁻³⁷. However, these reagents induce constitutive and sustained activation of the UPR, which usually results in the induction of the mitochondria-dependent intrinsic apoptotic pathways³⁸⁻⁴⁰,
 30 even in the absence of pro-apoptotic stimuli such as TRAIL^{37, 40}.

Modern understanding of the intimate associations between host and the microbiota⁴¹, suggest that microbes have evolved subtle and selective strategies to collaborate with host's biology^{1, 42}. Normally many bacterial products induce inflammatory processes, which are a risk factor commonly associated with the

development of cancer and autoimmune diseases^{17, 43}. However, it is not a case for other bacterial molecules. For example, our recent findings revealed that C12 possesses strong anti-inflammatory activity¹⁷. Moreover, the realization that C12 also induces the UPR prompted us to explore its potential as a complement for
 5 anti-cancer therapy.

To test this hypothesis, we examined the effect of C12 *in vitro* on the activity of TRAIL against A549 cell line derived from a cancer sample of the human lung. Consistent with the reported observation on A549 cells²⁸(Ashkenazi A et al., 1999), *in vitro* addition of TRAIL (50 ng/ml) to the
 10 cultured A549 cells did not significantly affect their viability and growth. However, the viability of A549 cells were dramatically reduced when a combination of TRAIL (50 ng/ml) and C12 (1 μ M) was added to the cultured medium (Fig. 4), although the cell growth and viability was practically unchanged in the presence of C12 (1 μ M or 25 μ M), its unnatural stereoisomer
 15 C12R (25 μ M) or a combination of TRAIL (50 ng/ml) and C12R (25 μ M) (Fig. 4A). Titration experiments revealed that more than 50% of cells lost their viability after a 24-hours incubation in the cultured medium with 100 nM of C12 and 50 ng/ml of TRAIL (Fig. 4B). These data support our assumption that resistance to TRAIL-mediated apoptosis might be overcome in the presence of
 20 C12.

To address whether C12 increases the pro-apoptotic effect of TRAIL against cancerous cells, we compared responses of A549 cells to TRAIL, C12 or TRAIL+C12 by Western blot analysis for several biochemical parameters relevant to the regulation of apoptosis and cell growth as well as cellular stress
 25 responses. Namely, the cleavage of poly(ADP-ribose) polymerase (PARP) and caspase-3 were used as two common markers indicative of processes induced through both the extrinsic and intrinsic apoptotic pathways^{26, 44}; we also examined the cleavage of caspase-9 as a marker indicative of the intrinsic apoptotic pathway⁴⁵; activation of the protein kinase JNK pathway, a hallmark of
 30 the mammalian stress response linked to cell growth control⁴⁶⁻⁴⁸, was tested by the analysis for the phosphorylation of JNK. To monitor the activity of C12, we analyzed the phosphorylation of eIF2 α , a distinct feature of ER stress^{11, 49}, and the phosphorylation of the protein kinase p38, an additional marker of the mammalian stress response⁵⁰. The results of these experiments revealed that the

stimulation with C12 resulted in rapid and strong activation of the stress responses with similar kinetics for all three markers, although apoptotic signaling was not induced at any time point tested (Fig. 5). In contrast, TRAIL treatment was certainly calm for activation of eIF2 α phosphorylation and other markers of the stress responses, although we noted barely detectable p38 and JNK phosphorylation at 6-hour time point; also, we observed the expected activation of caspase-3 leading to subsequent cleavage of PARP (see Fig 5). Notably, substantial changes of both the apoptotic and stress response markers were evident in cells treated with a combination of TRAIL and C12 at late time points (Fig. 5; compare the 2- and 6-hour time points).

Similar studies on a panel of other cancerous and normal cells confirmed these observations and demonstrated that C12 substantially sensitized different cancerous cells to TRAIL-mediated apoptosis, whereas normal cells were completely resistant (Fig. 6, Fig. 7 and Table 2), consistent with our previous observations when TNF was used instead of TRAIL (see above Fig. 3). Thus, reciprocal synergism between C12- and TRAIL- or TNF-mediated signaling results in prominent pro-apoptotic effect against cancerous cells, suggesting that the application of C12 might uncover new anti-cancer therapeutic strategies.

Bortezomid (also known as velcade) is an anti-cancer drug that strongly sensitizes cancerous cells to TRAIL-induced apoptosis⁵¹⁻⁵³. Therefore, to assess a potential utility of C12 for anti-cancer therapy, we compared the effects of these two compounds – (C12) and bortezomid (Bor) – on TRAIL-mediated apoptosis in cancerous A549 cells and primary human hepatocytes. The comparable increase in sensitivity of A549 cells to TRAIL was observed in the presence of either Bor or (C12) (Fig. 8A, top panel); also, similar levels of PARP cleavage (an apoptotic marker) were induced in response to a combination of TRAIL with Bor or (C12) (Fig. 7, bottom panel). Viability of normal human hepatocytes was unchanged in the presence of TRAIL (Fig. 8B, top panel); also, TRAIL-treated hepatocytes exhibited no evidence of apoptosis (Fig. 8B bottom panel). Similar examination of Bor-treated samples revealed that although this drug alone exhibited relatively low levels of toxicity toward hepatocytes, Bor-mediated toxicity as well as Bor-induced apoptosis was substantially enhanced in the presence of TRAIL (see Fig. 8B). In contrast, the hepatocytes were practically healthy and intact in the presence of (C12) or its

combination with TRAIL (see Fig. 8B). Thus, (C12) possesses potent anticancer activity without significant toxicity toward non-cancerous cells.

Since (C12) is a prototypic member of the 3-oxo-AHL family, the structure-activity-relation (SAR) investigations were warranted to determine generic structural features of AHL, which are required for a cancer-stop and cancer preventing activity as well as for activation of the UPR. To address this questions, a set of AHLs and their analogs were synthesized (see List of AHLs and analogs), and the biological activity of all compounds were examined on a panel of cancerous and normal cells. The prototypic examples of biochemical data for the selected analogs are shown in Fig. 9 and Fig. 10, whereas Table 2 summarizes the SAR studies for all compounds. These comprehensive SAR studies identified several analogs (13, 15 and 16, see Table 1, below) of (C12), which possess (C12) -like effect on mammalian cells. Moreover, similar to (C12), all three analogs strongly sensitize a number of cancerous cells to TRAIL-mediated apoptosis, suggesting that their application might lead to new anti-cancer therapeutic strategies.

Documents cited:

1. Backhed, F.; Ley, R. E.; Sonnenburg, J. L.; Peterson, D. A.; Gordon, J. I., Host-bacterial mutualism in the human intestine. *Science* 2005, 307 (5717), 1915-20.
2. Cani, P. D.; Delzenne, N. M., Gut microflora as a target for energy and metabolic homeostasis. *Curr Opin Clin Nutr Metab Care* 2007, 10 (6), 729-34.
3. Cebra, J. J., Influences of microbiota on intestinal immune system development. *Am J Clin Nutr* 1999, 69 (5), 1046S-1051S.
4. Janeway, C. A., Jr.; Medzhitov, R., Innate immune recognition. *Annu Rev Immunol* 2002, 20, 197-216.
5. Hotamisligil, G. S., Inflammation and metabolic disorders. *Nature* 2006, 444 (7121), 860-7.
6. Maslowski, K. M.; Mackay, C. R., Diet, gut microbiota and immune responses. *Nat Immunol* 12 (1), 5-9.
7. Wolowczuk, I.; Verwaerde, C.; Viltart, O.; Delanoye, A.; Delacre, M.; Pot, B.; Grangette, C., Feeding our immune system: impact on metabolism. *Clin Dev Immunol* 2008, 2008, 639803.

8. Ley, R. E.; Turnbaugh, P. J.; Klein, S.; Gordon, J. I., Microbial ecology: human gut microbes associated with obesity. *Nature* 2006, 444 (7122), 1022-3.
9. Hotamisligil, G. S.; Erbay, E., Nutrient sensing and inflammation in metabolic diseases. *Nat Rev Immunol* 2008, 8 (12), 923-34.
- 5 10. Hannun, Y. A.; Obeid, L. M., Principles of bioactive lipid signalling: lessons from sphingolipids. *Nat Rev Mol Cell Biol* 2008, 9 (2), 139-50.
11. Ron, D.; Walter, P., Signal integration in the endoplasmic reticulum unfolded protein response. *Nat Rev Mol Cell Biol* 2007, 8 (7), 519-29.
12. Kravchenko, V. V.; Kaufmann, G. F.; Mathison, J. C.; Scott, D. A.; Katz, A. Z.; Wood, M. R.; Brogan, A. P.; Lehmann, M.; Mee, J. M.; Iwata, K.; Pan, Q.; Fearn, C.; Knaus, U. G.; Meijler, M. M.; Janda, K. D.; Ulevitch, R. J., N-(3-oxo-acyl)homoserine lactones signal cell activation through a mechanism distinct from the canonical pathogen-associated molecular pattern recognition receptor pathways. *J Biol Chem* 2006, 281 (39), 28822-30.
- 10 13. Edrington, T. S.; Farrow, R. L.; Sperandio, V.; Hughes, D. T.; Lawrence, T. E.; Callaway, T. R.; Anderson, R. C.; Nisbet, D. J., Acyl-homoserine-lactone autoinducer in the gastrointestinal [corrected] tract of feedlot cattle and correlation to season, *E. coli* O157:H7 prevalence, and diet. *Curr Microbiol* 2009, 58 (3), 227-32.
- 15 14. Kumari, A.; Pasini, P.; Daunert, S., Detection of bacterial quorum sensing N-acyl homoserine lactones in clinical samples. *Anal Bioanal Chem* 2008, 391 (5), 1619-27.
15. Hughes, D. T.; Terekhova, D. A.; Liou, L.; Hovde, C. J.; Sahl, J. W.; Patankar, A. V.; Gonzalez, J. E.; Edrington, T. S.; Rasko, D. A.; Sperandio, V., Chemical sensing in mammalian host-bacterial commensal associations. *Proc Natl Acad Sci U S A* 107 (21), 9831-6.
- 25 16. Irazoqui, J. E.; Troemel, E. R.; Feinbaum, R. L.; Luhachack, L. G.; Cezairliyan, B. O.; Ausubel, F. M., Distinct pathogenesis and host responses during infection of *C. elegans* by *P. aeruginosa* and *S. aureus*. *PLoS Pathog* 6, e1000982.
- 30 17. Kravchenko, V. V.; Kaufmann, G. F.; Mathison, J. C.; Scott, D. A.; Katz, A. Z.; Grauer, D. C.; Lehmann, M.; Meijler, M. M.; Janda, K. D.; Ulevitch, R. J., Modulation of gene expression via disruption of NF-kappaB signaling by a bacterial small molecule. *Science* 2008, 321 (5886), 259-63.

18. Cox, J. S.; Chapman, R. E.; Walter, P., The unfolded protein response coordinates the production of endoplasmic reticulum protein and endoplasmic reticulum membrane. *Mol Biol Cell* 1997, 8 (9), 1805-14.
19. Merrill, A. H., Jr., De novo sphingolipid biosynthesis: a necessary, but
5 dangerous, pathway. *J Biol Chem* 2002, 277 (29), 25843-6.
20. Yatomi, Y.; Ruan, F.; Megidish, T.; Toyokuni, T.; Hakomori, S.; Igarashi, Y., N,N-dimethylsphingosine inhibition of sphingosine kinase and sphingosine 1-phosphate activity in human platelets. *Biochemistry* 1996, 35 (2), 626-33.
21. Suzuki, E.; Handa, K.; Toledo, M. S.; Hakomori, S., Sphingosine-dependent apoptosis: a unified concept based on multiple mechanisms operating in concert. *Proc Natl Acad Sci U S A* 2004, 101 (41), 14788-93.
22. Cuvillier, O., Sphingosine in apoptosis signaling. *Biochim Biophys Acta* 2002, 1585 (2-3), 153-62.
23. Ohta, H.; Yatomi, Y.; Sweeney, E. A.; Hakomori, S.; Igarashi, Y., A possible role of sphingosine in induction of apoptosis by tumor necrosis factor- α in human neutrophils. *FEBS Lett* 1994, 355 (3), 267-70.
24. Spiegel, S.; Milstien, S., Sphingosine-1-phosphate: signaling inside and out. *FEBS Lett* 2000, 476 (1-2), 55-7.
25. Spiegel, S., Sphingosine 1-phosphate: a ligand for the EDG-1 family of G-protein-coupled receptors. *Ann N Y Acad Sci* 2000, 905, 54-60.
26. Nicholson, D. W.; Ali, A.; Thornberry, N. A.; Vaillancourt, J. P.; Ding, C. K.; Gallant, M.; Gareau, Y.; Griffin, P. R.; Labelle, M.; Lazebnik, Y. A.; et al., Identification and inhibition of the ICE/CED-3 protease necessary for
25 mammalian apoptosis. *Nature* 1995, 376 (6535), 37-43.
27. Ashkenazi, A., Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. *Nat Rev Drug Discov* 2008, 7 (12), 1001-12.
28. Ashkenazi, A.; Pai, R. C.; Fong, S.; Leung, S.; Lawrence, D. A.; Marsters, S. A.; Blackie, C.; Chang, L.; McMurtrey, A. E.; Hebert, A.; DeForge,
30 L.; Koumenis, I. L.; Lewis, D.; Harris, L.; Bussiere, J.; Koeppen, H.; Shahrokhi, Z.; Schwall, R. H., Safety and antitumor activity of recombinant soluble Apo2 ligand. *J Clin Invest* 1999, 104 (2), 155-62.
29. Waleczak, H.; Miller, R. E.; Ariail, K.; Gliniak, B.; Griffith, T. S.; Kubin, M.; Chin, W.; Jones, J.; Woodward, A.; Le, T.; Smith, C.; Smolak, P.; Goodwin,











- R. G.; Rauch, C. T.; Schuh, J. C.; Lynch, D. H., Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. *Nat Med* 1999, 5 (2), 157-63.
30. Lippa, M. S.; Strockbine, L. D.; Le, T. T.; Branstetter, D. G.; Strathdee, C. A.; Holland, P. M., Expression of anti-apoptotic factors modulates
5 Apo2L/TRAIL resistance in colon carcinoma cells. *Apoptosis* 2007, 12 (8), 1465-78.
31. Beg, A. A.; Baltimore, D., An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. *Science* 1996, 274 (5288), 782-4.
- 10 32. Wang, C. Y.; Mayo, M. W.; Baldwin, A. S., Jr., TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. *Science* 1996, 274 (5288), 784-7.
33. Van Antwerp, D. J.; Martin, S. J.; Kafri, T.; Green, D. R.; Verma, I. M., Suppression of TNF-alpha-induced apoptosis by NF-kappaB. *Science* 1996, 274
15 (5288), 787-9.
34. Liu, Z. G.; Hsu, H.; Goeddel, D. V.; Karin, M., Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. *Cell* 1996, 87 (3), 565-76.
35. Jiang, C. C.; Chen, L. H.; Gillespie, S.; Kiejda, K. A.; Mhaidat, N.;
20 Wang, Y. F.; Thorne, R.; Zhang, X. D.; Hersey, P., Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. *Cancer Res* 2007, 67 (12), 5880-8.
36. Chen, L. H.; Jiang, C. C.; Kiejda, K. A.; Wang, Y. F.; Thorne, R. F.;
25 Zhang, X. D.; Hersey, P., Thapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein response. *Carcinogenesis* 2007, 28 (11), 2328-36.
37. Tiwary, R.; Yu, W.; Li, J.; Park, S. K.; Sanders, B. G.; Kline, K., Role of endoplasmic reticulum stress in alpha-TEA mediated TRAIL/DR5 death
30 receptor dependent apoptosis. *PLoS One* 5 (7), e11865.
38. Szegezdi, E.; Logue, S. E.; Gorman, A. M.; Samali, A., Mediators of endoplasmic reticulum stress-induced apoptosis. *EMBO Rep* 2006, 7 (9), 880-5.

39. Gupta, S.; Cuffe, L.; Szegezdi, E.; Logue, S. E.; Neary, C.; Healy, S.; Samali, A., Mechanisms of ER Stress-Mediated Mitochondrial Membrane Permeabilization. *Int J Cell Biol* 2010, 170215.
40. Szegezdi, E.; Cahill, S.; Meyer, M.; O'Dwyer, M.; Samali, A., TRAIL
5 sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. *Br J Cancer* 2006, 94 (3), 398-406.
41. Savage, D. C., Microbial ecology of the gastrointestinal tract. *Annu Rev Microbiol* 1977, 31, 107-33.
42. Hsiao, W. W.; Metz, C.; Singh, D. P.; Roth, J., The microbes of the
10 intestine: an introduction to their metabolic and signaling capabilities. *Endocrinol Metab Clin North Am* 2008, 37 (4), 857-71.
43. Telford, G.; Wheeler, D.; Williams, P.; Tomkins, P. T.; Appleby, P.; Sewell, H.; Stewart, G. S.; Bycroft, B. W.; Pritchard, D. I., The *Pseudomonas aeruginosa* quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine
15 lactone has immunomodulatory activity. *Infect Immun* 1998, 66 (1), 36-42.
44. Gyrd-Hansen, M.; Meier, P., IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. *Nat Rev Cancer* 10 (8), 561-74.
45. Green, D. R.; Reed, J. C., Mitochondria and apoptosis. *Science* 1998, 281 (5381), 1309-12.
- 20 46. Brenner, D. A.; O'Hara, M.; Angel, P.; Chojkier, M.; Karin, M., Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha. *Nature* 1989, 337 (6208), 661-3.
47. Schreiber, M.; Kolbus, A.; Piu, F.; Szabowski, A.; Mohle-Steinlein, U.; Tian, J.; Karin, M.; Angel, P.; Wagner, E. F., Control of cell cycle progression
25 by c-Jun is p53 dependent. *Genes Dev* 1999, 13 (5), 607-19.
48. Shaulian, E.; Schreiber, M.; Piu, F.; Beeche, M.; Wagner, E. F.; Karin, M., The mammalian UV response: c-Jun induction is required for exit from p53-imposed growth arrest. *Cell* 2000, 103 (6), 897-907.
49. Schroder, M.; Kaufman, R. J., The mammalian unfolded protein
30 response. *Annu Rev Biochem* 2005, 74, 739-89.
50. Ono, K.; Han, J., The p38 signal transduction pathway: activation and function. *Cell Signal* 2000, 12 (1), 1-13.

51. Christian, P. A.; Thorpe, J. A.; Schwarze, S. R., Velcade sensitizes prostate cancer cells to TRAIL induced apoptosis and suppresses tumor growth in vivo. *Cancer Biol Ther* 2009, 8 (1), 73-80.
52. Arpinati, M.; Chirumbolo, G.; Nicolini, B.; Agostinelli, C.; Rondelli, D.,
5 Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade). *Bone Marrow Transplant* 2009, 43 (3), 253-9.
53. Pandit, B.; Gartel, A. L., Proteasome inhibitors induce p53-independent apoptosis in human cancer cells. *Am J Pathol* 178 (1), 355-60.

10

Table 1: Compounds Evaluated

Compound #	Structure	LogP (est.)
1 C12		2.685
2 C12R		2.685
3		0.569
4		1.627
5		3.743
6		3.743
7		2.569
8		3.718
9		-0.514
10		3.299











11		1.856
12		-0.26
13 (12-N ₃ -12)		2.958
14		2.958
15 3-N ₂		3.202
16 12-N ₃ -3-N ₂		3.475
17 12-N ₃ -6-N ₂ -12		1.71
18		0.079
19		2.64
20		2.64

Table 2. Biological activities of compounds (naturally occurring or synthetic derivatives of *N*-acylhomoserine lactones) synthesized for structure-activity-relation studies in mammalian cells.

Compound	Natural (n) or synthetic (s)	Efficiency of PARP cleavage (%)*	Efficiency of the p38 activation (%)*	Efficiency of the UPR activation (%)*	Effect on cancer cells: synergy with TRAIL or TNF
1	n	100	100	100	++++
2	s	<0.1	<0.1	<0.1	-
3	n	<0.1	<0.1	<0.1	n.d.
4	n	~0.5	~2.0	~5.0	+
5	n	>100	>100	>100	++++
6	s	<0.1	<0.1	<0.1	-
7	s	<0.1	<0.1	<0.1	-
8	n	<0.1	<0.1	<0.1	-
9	n	<0.1	<0.1	<0.1	-
10	s	~10.0	~2.0	~1.0	n.d.
11	s	~1.0	~2.0	~2.0	n.d.
12	s	<0.1	<0.1	<0.1	-
13	s	~100	~100	~100	++++
14	s	<0.1	<0.1	<0.1	-
15	s	~30.0	~40.0	~40.0	+++
16	s	~60.0	~50.0	~70.0	++++
17	s	~10.0	~5.0	~10.0	+
18	s	~5.0	~2.0	~2.0	n.d.
19	s	<0.1	<0.1	<0.1	-
20	n	~1.0	~2.0	~2.0	+

5 *The activity of a compound was normalized to those for *N*-(3-oxo-dodecanoyl) homoserine lactone (compound # 1, also abbreviated in the text as (C12)).

Materials and Methods

A. General Methods

Cancer and normal cell culture. Lung cancer cell line A549 and colon cancer cell line HT29 were purchased from ATCC. Breast cancer cell line MDA-MB-468 was received from J.C. Reed (The Burnham Institute, La Jolla, California). Cell lines were maintained in growth medium (GM): DMEM medium (4.5 g/l

5 glucose) supplemented with 10% FBS (HyClone, Logan, UT), L-glutamine, penicillin/streptomycin and nonessential amino acids (Invitrogen, Carlsbad, CA). Normal human bronchial epithelial (NHBE) cells and normal human mammary epithelial (NHME) cells were obtained from Cambrex (East Rutherford, NJ) and cultured as recommended by the manufacturer. Normal human colon smooth

10 muscle cells were obtained from ScienCell Research Lab (San Diego, CA) and cultured as recommended by the manufacturer. Primary cultures of human hepatocytes (freshly plated; not cryopreserved) and culture medium were obtained from Celsis In Vitro Technologies (Baltimore, MD). Upon receipt of the cells, the medium was gently aspirated from each well and replenished with

15 InVitroGRO HI medium supplemented with Torpedo Antibiotic Mix (Celsis), and the plates were kept in a 5% CO₂ at 37 °C in an incubator at saturating humidity. After 2–4 h, cells were stimulated as described in the text and figure legends.

Mice, bone marrow-derived macrophages and other cell culture. C57BL/6 mice

20 were purchased from the Jackson Laboratory (Bar Harbor, ME). Bone marrow-derived macrophages (BMDM) and murine embryonic fibroblasts (MEF) were prepared by using standard protocols that were approved by the TSRI Animal Care and Use Committee. L929/NCTC clone 929 (connective tissue, mouse) cell lines were purchased from ATCC (Manassas, VA). MEFs and L929 cell line

25 were maintained in GM (see above). BMDM were cultured in 70% GM and 30% L929 conditioned medium. In general, cells (~60–70% confluence) were incubated in fresh medium for 12–14 h before stimulation.

Bacterial culture. *Pseudomonas aeruginosa* bacterial strains used in our studies were kindly provided by Dr. Scott A. Beatson, University of Queensland,

30 Brisbane, Australia and include wild type *Pseudomonas aeruginosa* PAO1 (originally from ATCC) and PAO1 Δ lasI. Bacterial strains used for control studies include *Acinetobacter baumannii*, *Escherichia coli*, *Staphylococcus aureus* and *Salmonella typhimurium*, all from ATCC.

Reagents and standard assay. Recombinant human TRAIL was purchased from R&D System, Inc (Minneapolis, MN), and was used for cell stimulation in all experiments at a concentration of 20 ng/ml or as indicated in the figure legends. Bacterial culture of *E. coli* expressing recombinant protein, a variant 118-291 of mTRAIL, was used for the preparation of recombinant murine TRAIL isolated by standard ion-exchange chromatography on DE52 and hydroxyapatite. *S. minnesota* Re595 LPS was prepared as previously described.^{E1} All acylhomoserine lactones, including *N*-(3-oxododecanoyl)-*S*- and -*R*-homoserine lactone (C12 and C12R, respectively), were synthesized and purified as previously described.^{E2} The purity was greater than 99% and was confirmed by HPLC/mass spectrometry analysis. All synthetic molecules were dissolved in DMSO at 200x of the desired concentration and aliquots were stored at -20 °C. In addition, a quantitative QCL-1,000 chromogenic Limulus amoebocyte lysate assay (BioWhittaker, Walkersville, MD) demonstrated that preparations of C12 were endotoxin free. Supernatant levels of TNF in the samples were measured by ELISA (BD Biosciences Pharmingen, San Diego, CA). Total RNA was isolated by using TRizol reagent (Invitrogen).

Antibodies and Western blot analysis. Anti-eIF2 α , phospho-eIF2 α (p-eIF2 α), p38, p-p38 (Thr180/Tyr132), p-RelA (Ser536), p-I κ B Ser32/36, PARP antibodies were purchased from Cell Signaling; anti-RelA, I κ B α , I κ B β were from Santa Cruz Biotechnology. Cellular extracts were prepared and analyzed by Western blot assay as previously described.^{E3}

Data presentation. The data depicted in Figures 11–13 represent one of three or more experiments with each graph reflecting findings typical of multiple studies.

General chemistry methods: Reactions were carried out under a nitrogen atmosphere with dry, freshly distilled solvents under anhydrous conditions, unless otherwise noted. Methylene chloride (CH₂Cl₂) was distilled from calcium hydride. Tetrahydrofuran (THF) was distilled from sodium-benzophenone. Yields refer to chromatographically and spectroscopically homogenous materials, unless otherwise stated. Reactions were monitored by thin-layer chromatography (TLC) carried out on 0.25-mm EMD silica gel plates (60F-254) using anisaldehyde, KMnO₄ or PMA staining. Flash chromatography separations were performed on Silicycle silica gel (40-63 mesh). NMR spectra were recorded on Bruker 400 MHz spectrometers and calibrated using a solvent peak

7.2 Hz), 1.56–1.53 (m, 2H), 1.44 (s, 9H), 1.21–1.18 (m, 12H), 0.85 (t, 3H, $J = 6.8$ Hz).

Preparation of 4. Compound **3** (1.34 g, 5.0 mmol) was added to a round-bottom flask at 25 °C and dissolved in ethylene glycol (910 mg, 14.75 mmol) and methylene chloride (30 mL). TMSCl (3.2 g, 3.7 mL, 29.5 mmol) was then added to the stirring solution dropwise at 25 °C. The resulting mixture was stirred for 4 days at 25 °C and then quenched with water (15 mL) and extracted with methylene chloride (2 × 20 mL). The combined organic phases were dried with Na₂SO₄ and concentrated *in vacuo*. This protected material was used as crude for the subsequent reaction. Crude ethylene glycol-protected **3** was added to a round-bottom flask and dissolved in THF (40 mL) under nitrogen atmosphere at 0 °C. Lithium aluminum hydride (1.0 M in hexane, 1.5 equiv) was added dropwise, and the reaction mixture was allowed to warm to 25 °C. After stirring for 4 h, the reaction was quenched with water and filtered. The filtrate was concentrated to ~20 mL, 1 M HCl (20 mL) was added and the mixture was stirred overnight at 25 °C. The reaction mixture was then extracted with EtOAc (2 × 30 mL), and the combined organic phases were dried with Na₂SO₄ and concentrated *in vacuo*. The resulting residue was purified by flash column chromatography (3:1 hexanes in EtOAc) to obtain **4** (1.0 g, 80% yield over 3 steps). The characterization data for **4** matched that previously reported.^{E5} ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 3.82 (t, 2H, $J = 5.4$ Hz), 2.64 (t, 2H, $J = 5.2$ Hz), 2.39 (t, 2H, $J = 5.2$ Hz), 1.56–1.54 (m, 2H), 1.26–1.23 (m, 12H), 0.86 (t, 3H, $J = 6.8$ Hz).

Preparation of 5. The protocol for diazirine installation followed that previously reported.³ Compound **4** (489 mg, 2.44 mmol) was added to a round bottom flask equipped with a condenser and dissolved in methanol (8 mL). Liquid ammonia (30 mL) was added, and the stirring solution was heated to reflux for 7 h. The resulting mixture was cooled in a dry ice-acetone bath, and a solution of NH₂OSO₃H (332 mg, 2.93 mmol) in methanol (10 mL) was added over 5 min. The cooling bath was removed, and the mixture was heated to reflux for 1 h. Following overnight evaporation of the liquid ammonia, the reaction mixture was filtered, and the filter cake was washed with methanol. The filtrate and washings were concentrated *in vacuo*, and the crude diazirine was used as crude

for the subsequent oxidation reaction. Oxidation of the crude diaziridine to diazirine **5** was performed using the iodine-Et₃N method previously described,^{E6} and the compound was obtained following flash column chromatography (120 mg, 23 % yield). ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 3.44 (t, 2H, *J* = 6.4 Hz), 1.64 (t, 2H, *J* = 6.4 Hz), 1.37 (t, 2H, *J* = 6.4 Hz), 1.26–1.17 (m, 14H), 0.87 (t, 3H, *J* = 6.8 Hz); ¹³C NMR (100 MHz, CDCl₃, 25 °C): δ = 170.1, 52.6, 49.8, 46.9, 31.9, 29.6, 29.6, 29.6, 29.3, 22.7, 19.4, 14.1; HRMS (ESI-TOF) *m/z* calcd for C₁₂H₂₄N₂O [M+H]⁺ 212.1889, found 212.1318.

Preparation of 3-N₂. The primary alcohol of diazirine **5** was oxidized to the corresponding acid using standard Jones oxidation conditions. ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 2.28 (d, 2H, *J* = 4.4 Hz), 1.53–1.51 (m, 2H), 1.26–1.17 (m, 14H), 0.84 (t, 3H, *J* = 6.8 Hz); ¹³C NMR (100 MHz, DMSO, 25 °C): δ = 177.3, 168.9, 52.4, 46.3, 31.9, 29.6, 29.6, 29.6, 29.3, 22.7, 19.1, 14.1; HRMS (ESI-TOF) *m/z* calcd for C₁₂H₂₂N₂O₂ [M+H]⁺ 226.1681, found 226.1653. The acid was converted to the corresponding acid chloride using oxalyl chloride and coupled to (*S*)-α-Amino-γ-butyrolactone as previously described.^{E7,E8} ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 6.24 (app s, 1H), 4.57–4.47 (m, 2H), 4.32–4.29 (m, 1H), 2.88–2.85 (m, 1H), 2.27–2.2 (m, 3H), 1.53 (t, 2H, *J* = 6.8 Hz), 1.26–1.15 (m, 14H), 0.87 (t, 3H, *J* = 6.8 Hz); ¹³C NMR (100 MHz, DMSO, 25 °C): δ = 190.0, 175.4, 168.9, 66.3, 49.6, 41.4, 32.7, 29.6, 29.5, 29.4, 29.2, 24.0, 14.3, 14.2 (14 found); HRMS (ESI-TOF) *m/z* calcd for C₁₆H₂₇N₃O₃ [M+H]⁺ 309.2052, found 309.2039.

C. Bacterial Experiments

Exposure of cancer cells to bacterial culture.

We utilized experimental systems in which products released by bacteria can interact with eukaryotic targets while avoiding direct contact of bacteria with cells in tissue culture. The inserts containing bacterial cultures were placed in close proximity to cultured lung cancer cells that were left untreated or treated with TRAIL (TRAIL was added directly into GM media at the same time). We used a custom fabricated insert prepared from cut polystyrene tubing (14 mm diameter x 25 mm height) with a solvent-welded polyvinylidene fluoride membrane base (PVDF Durapore hydrophilic 0.1 μm membrane, Millipore VVLP09050). To prepare these inserts, one end of the cut polystyrene tubing is

dipped into methylene chloride for 5 seconds, and the softened plastic is pressed onto the surface of a cut section of PVDF membrane for 0.5 min. The softened polystyrene flows into the PVDF sufficiently to form an impervious bond without damaging the membrane pore structure. After allowing a few hours for the solvent to completely evaporate, inserts are immersed in 1% hypochlorite for 30 minutes followed by 6 rinses with sterile saline (performed in a laminar flow hood). The 14 mm diameter insert is an optimal fit for the 24-well plate, with the internal area of the insert covering ~70% of the well surface.

We used the prototype 0.1 μ m PVDF membrane inserts for studies in which tissue culture cells are exposed to soluble products derived from *P. aeruginosa* PAO1 (wild type), PAO1 Δ lasI, *S. aureus*, *S. typhimurium*, *A. baumannii* and *E. coli*. The bacteria were grown on BHI agar plates, transferred to inoculum culture overnight followed by 1/100 dilution into 20 ml BHI broth in 125 ml baffled shake flasks for incubation at 37 °C, 250 rpm for 4-6 hr. The equal aliquots of the late log phase culture or control BHI broth were transferred to PVDF inserts which were placed in 24-well plates containing target cells cultured in 0.5 ml DMEM growth medium.

Determination of C12 concentration in bacterial cultures. A 2-ml culture was acidified with 50 μ l of HCl and 10 ml of ethyl acetate was added, and the contents were mixed vigorously. The layers were allowed to separate, and 5 ml of the ethyl acetate layer were removed, dried over MgSO₄, and concentrated in vacuo. The residue was resuspended in cold methanol and centrifuged to remove the precipitate. The resulting methanol solution was analyzed by LC-MS (liquid chromatography – mass spectrometry) for C12 content. Reverse phase LC-MS analysis (Agilent Zorbax column, 5 μ m, 300SB-C8, 4.6 $\times$ 50 mm) was performed with gradients of MeCN–H₂O–0.1% formic acid (from 0 to 1 min: 5% MeCN, from 1 min to 9 min: gradient of 5% MeCN to 98% MeCN, and from 9 to 11 min: 98% MeCN) allowing for quantification of C12 by measuring the following ions: 298 (M + H⁺), 316 (M + H₂O + H⁺), 320 (M + Na⁺), and 338 (M + H₂O + Na⁺). The concentration of C12 in the samples of *P. aeruginosa* PAO1 (wild type) was about 4.3 μ M (P < 0.001, n = 5 independent experiments).

D. Mammalian Cell Activation

Cell stimulation. In all experiments, BMDM were stimulated with LPS (100 ng/ml), AHL (10-25 μ M; usually BMDM and primary macrophages were

stimulated by 25 μ M of C12) or their combination as indicated in the figure legends. If not indicated, cancer and normal cells were stimulated with 40 ng/ml of TNF α , 20 ng/ml TRAIL and 10 μ M (in case of cancer cells) or 25 μ M (in case of normal cells) of AHL.

5 E. Cell viability and assessment of apoptosis.

Cytotoxicity was determined by using the XTT-based toxicology assay kit (Sigma, St. Louis, MS) in accordance with the manufacturer's instructions. For some experiments, to confirm the apoptotic nature of toxicity, cells were analyzed using protocols and instructions of the Annexin V-FITC apoptosis
10 detection kit (Biovision, Mountain View, California). In addition, caspase 3, 8 and 9 activities were determined by colorimetric assays (R&D System), and the data are expressed as fold increases compared to the values of untreated or control-treated cells (n=5).

15 F. Experimental References Cited


- (E1) Mathison, J. C.; Virca, G. D.; Wolfson, E.; Tobias, P. S.; Glaser, K.; Ulevitch, R. J. *J. Clin. Invest.* **1990**, *85*, 1108.
- (E2) Kaufmann, G. F.; Sartorio, R.; Lee, S. H.; Rogers, C. J.; Meijler, M. M.; Moss, J. A.; Clapham, B.; Brogan, A. P.; Dickerson, T. J.; Janda, K. D. *Proc. Natl. Acad. Sci., U. S. A.* **2005**, *102*, 309.
- 20 (E3) Kravchenko, V. V.; Ulevitch, R. J.; Kaufmann, G. F. *Methods Mol. Biol.* **2010**, *692*, 133.
- (E4) Langer, P.; Bellur, E. *J. Org. Chem.* **2003**, *68*, 9742.
- (E5) Kirihaara, M.; Kakuda, H.; Ichinose, M.; Ochiai, Y.; Takizawa, S.;
25 Mokuya, A.; Okubo, K.; Hatano, A.; Shiro, M. *Tetrahedron* **2005**, *61*, 4831.
- (E6) Church, R. F. R.; Weiss, M. J. *J. Org. Chem.* **1970**, *35*, 2465.
- (E7) Kaufmann, G. F.; Sartorio, R.; Lee, S. H.; Mee, J. M.; Altobelli, L. J., 3rd; Kujawa, D. P.; Jeffries, E.; Clapham, B.; Meijler, M. M.; Janda, K. D. *J. Am. Chem. Soc.* **2006**, *128*, 2802.
- 30 (E8) Garner, A. L.; Yu, J.; Struss, A. K.; Lowery, C. A.; Zhu, J.; Kim, S. K.; Park, J.; Mayorov, A. V.; Kaufmann, G. F.; Kravchenko, V. V.; Janda, K. D. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 2702.

The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the
5 scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

CLAIMS


What is claimed is:

1. A pharmaceutical composition comprising an effective amount of an N-acylhomoserine lactone (AHL) analog compound of formula (I):




wherein R is a linear alkyl of 9 to 15 carbon atoms having one or more diazirenyl groups, optionally having one or more carbonyl groups, and further optionally substituted with azido; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.

2. The pharmaceutical composition of claim 1, wherein the compound is of formula (II)




wherein R¹ is a linear alkyl of 7 to 13 carbon atoms, optionally having one or more azido groups.

3. The pharmaceutical composition of claim 1 or 2, further comprising a tumor modulating agent that is a TRAIL polypeptide.
4. The pharmaceutical composition of any one of claims 1 to 3, wherein the N-acylhomoserine lactone (AHL) analog is selected from the group consisting of:




5. An N-acylhomoserine lactone (AHL) analog compound of formula (I)



wherein R is a linear alkyl of 9 to 15 carbon atoms having one or more diazirenyl groups, optionally having one or more carbonyl groups, and further optionally substituted with azido; or a pharmaceutically acceptable salt thereof; for use in treating a tumor in a patient.


6. The compound or pharmaceutically acceptable salt thereof for use of claim 5, wherein the compound is a compound of formula (II)



wherein R¹ is a linear alkyl of 7 to 13 carbon atoms, optionally having one or more azido groups.


7. The compound or pharmaceutically acceptable salt thereof for use of claim 5 or 6, further comprising use of a tumor modulating agent that is a TRAIL polypeptide.

8. The compound or pharmaceutically acceptable salt thereof for use of any one of claims 5 to 7, wherein the N-acylhomoserine lactone (AHL) analog is selected from the group consisting of:




9. The compound or pharmaceutically acceptable salt thereof for use of any one of claims 5 to 8, wherein the tumor is selected from the group consisting of lung, cervical, breast, and brain tumors.

10. A compound of formula (I):




wherein R is a linear alkyl of 9 to 15 carbon atoms having one or more diazirenyl groups, optionally having one or more carbonyl groups, and further optionally substituted with azido; or a pharmaceutically acceptable salt thereof.

11. The compound or pharmaceutically acceptable salt thereof of claim 10, wherein the compound is a compound of formula (II)




wherein R¹ is a linear alkyl of 7 to 13 carbon atoms, optionally having one or more azido groups.

12. The compound or pharmaceutically acceptable salt thereof of any one of claims 10 to 12, wherein the N-acylhomoserine lactone (AHL) analog is selected from the group consisting of:




13. An N-acylhomoserine lactone (AHL) compound of formula (I):



wherein R is a linear alkyl of 9 to 15 carbon atoms having one or more diazirenyl groups, optionally having one or more carbonyl groups, and further optionally substituted with azido, or a pharmaceutically acceptable salt thereof, and a TRAIL ligand, for use in inducing apoptosis, arrest of cell division, or inhibition of cell proliferation, in a tumor cell.


14. The N-acylhomoserine lactone (AHL) compound or pharmaceutically acceptable salt thereof and TRAIL ligand for use of claim 13, wherein the AHL compound is an activator of the unfolded protein response (UPR), of endoplasmic reticulum swelling (ERS), or both, in the tumor cell.

15. The N-acylhomoserine lactone (AHL) compound or pharmaceutically acceptable salt thereof and TRAIL ligand for use of claim 13 or 14 wherein the compound is a compound of formula (II)



wherein R¹ is a linear alkyl of 7 to 13 carbon atoms, optionally having one or more azido groups.





16. The N-acylhomoserine lactone (AHL) compound or pharmaceutically acceptable salt thereof and TRAIL ligand for use of any one of claims 13 to 15 wherein the N-acylhomoserine lactone (AHL) analog is selected from the group consisting of:



17. Use of the compound or pharmaceutically acceptable salt thereof of any one of claims 10 to 12 for treating a tumor in a patient.

18. The use of claim 17, wherein the compound or pharmaceutically acceptable salt thereof is for use with a tumor modulating agent that is a TRAIL polypeptide.
19. Use of the compound or pharmaceutically acceptable salt thereof of any one of claims 10 to 12 for the preparation of a medicament for treating a tumor in a patient.
20. The use of claim 19, wherein the medicament is for use with a tumor modulating agent that is a TRAIL polypeptide.
21. Use of the compound or pharmaceutically acceptable salt thereof of any one of claims 10 to 12 and a TRAIL ligand for inducing apoptosis, arrest of cell division, or inhibition of cell proliferation, in a tumor cell.
22. Use of the compound or pharmaceutically acceptable salt thereof of any one of claims 10 to 12 for the preparation of a medicament for inducing apoptosis, arrest of cell division, or inhibition of cell proliferation, in a tumor cell, wherein the medicament is for use with a TRAIL ligand.

1/16

*Fig. 1A**Fig. 1B**Fig. 1C**Fig. 1D*

2/16




Fig. 1F




Fig. 1E











Fig. 1G





3/16

*Fig. 2A**Fig. 2B**Fig. 2C**Fig. 2D*

4/16

*Fig. 2E**Fig. 2F*

5/16

*Fig. 3A**Fig. 3B**Fig. 3C*

6/16








Fig. 4A

Fig. 4B


7/16

*Fig. 5*


8/16

*Fig. 6A*

Tg:	-	-	-	+	-	+
C12:	-	-	+	-	+	-
TRAIL:	-	+	-	-	+	+

*Fig. 6B*

9/16

*Fig. 7*




Fig. 8A








Fig. 8B


11/16

*Fig. 9A**Fig. 9B*

12/16




*Fig. 10A**Fig. 10B*





13/16






AHL: R: H, OH or =O; n = 2 - 10

C12: R: =O; n=8



Fig. 11A*Fig. 11B**Fig. 11C**Fig. 11D*




15/16


*Fig. 13A**Fig. 13B**Fig. 13C*

16/16

*Fig. 13D**Fig. 13E*



(I);



(II).